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ABSTRACT 
Chronic kidney disease (CKD) is defined as a loss of renal function from any cause and 
lasting for more than three months. The CKD phenotype is similar across multiple 
etiologies, suggesting that renal damage itself is a dominant factor. Thus, regardless of 
the cause even a moderate loss of renal function is associated with impaired hepatic 
metabolism of glucose, cholesterol, lipid particles, bile acids and plasma proteins. There 
are surprisingly few studies investigating a putative contribution of this impaired 
hepatic metabolism to the phenotype of CKD. The overall aim of the current thesis was 
thus to investigate a hypothetical impact on certain well-characterized hepatic signaling 
pathways in uremic patients and through both clinical and experimental studies. 
In Paper I, we describe the release of FGF-19 to the blood, following a meal 
provocation rich in energy and fat given to CKD patients with severely impaired renal 
function as well as to age- and gender-matched healthy subjects. We report that the 
expected increase in postprandial FGF-19 appears to be blunted in CKD patients due to 
other reasons than delayed gastric emptying. Seven days of pre-treatment with either 
one of the natural anti-oxidants N-acetylcysteine or anthocyanins led to a partial 
normalization of postprandial FGF-19 release. 
In Papers II and III, primary cultures of human hepatocytes were used to study intra-
cellular metabolic signaling under uremic conditions in vitro. We designed and used a 
model entailing culture of these cells (isolated from resected livers) together with CKD 
patient or healthy sera. We found that hepatocytes exposed to uremic sera rapidly 
develop an unhealthy metabolism characterized by increased gluconeogenesis and 
lipogenesis accompanied by perturbations of several key cellular signaling networks. 
We found no effects of uremic sera on FGF-19 receptor signaling, bile acid synthesis or 
bile composition. 
In Paper IV, we investigated the role of hepatic metabolism on systemic FGF-19 levels. 
Portal and systemic (peripheral arterial and central venous) blood concentrations of 
FGF-19 and bile acids were assessed in 75 non-CKD patients undergoing liver surgery. 
We found no differences of FGF-19 concentrations between portal and systemic blood. 
Furthermore, treatment of primary hepatocytes with FGF-19 in vitro inhibited CYP7A1 
expression only at supra-physiological concentrations (2.3-fold decrease) while 
physiological concentrations of the bile acid CDCA elicited a 12-fold decrease. We 
conclude that systemic blood concentrations of FGF-19 can be considered to mirror 
portal concentrations at least in non-CKD populations.   
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1 INTRODUCTION 
1.1 THE HUMAN KIDNEY 
1.1.1 Renal anatomy 
In humans the two kidneys are located outside the peritoneum, against the back of the 
abdominal cavity and on either side of the spine. The right kidney sits just below the liver 
and is therefore slightly smaller and lower than the left which sits approximately level 
with vertebras T12-Ll, below the diaphragm and behind the spleen. The kidneys are 
normally partially covered by the 11th and 12th ribs. Just above each kidney sits the 
adrenal gland, while the whole complex is surrounded by perirenal fat, pararenal fat and 
the renal fascias. In adult humans, an individual kidney is approximately 11–14 cm in 
length, 6 cm wide and 4 cm thick, weighing around 150 grams. 
The kidneys are “bean-shaped” structures with a convex and a concave aspect. On the 
concave aspect sits the renal hilum, the recessed area housing the renal artery, the renal 
vein, lymphatic vessels and the ureter. The surface of each kidney consists of a fibrous 
capsule. Inside, the parenchyma of each kidney is divided in outer portion renal cortex 
and inner portion renal medulla, with 10-20 cone-shaped renal lobes, called a renal 
pyramid. The nephron forms the basic structural and functional unit of the kidney, which 
each contain approximately 1 million of these distributed across both the cortex and 
medulla, Below these two layers of nephrons lie first the minor and then the major 
calyces, leading the urine into the renal pelvis , whence it travels down the ureters and 
into the urinary bladder.  
            
Figure 1. Cross-section through the kidney with key anatomical structures indicated. Source: Anatomy & Physiology, 
Connexions Web site. http://cnx.org/content/col11496/1.6/ (Jun 19, 2013). Published under Creative Commons Attribution 3.0 license. 
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The kidneys are supplied with oxygenated blood through the renal arteries, which in turn 
branch directly off the abdominal aorta.  After entering the renal hilum, the blood flows 
into many segmental arteries and on to the interlobar arteries, arcuate arteries (which pass 
through the border of the renal cortex and medulla), interlobular arteries and finally into 
the afferent arterioles of each nephron. Following filtration in the glomerulus, efferent 
arterioles carry the unfiltered portion on into peritubular capillaries that supply the distal 
tubules and other structures of the renal cortex. The blood from these capillaries then 
drains into interlobular veins, which combine into larger venules, veins and finally back 
through the two renal veins into the inferior vena cava (Figure 1 and Figure 2).  
1.1.2 The nephron 
The nephron is the functional filtration unit of the kidneys, each comprising a complex of 
interconnected capillary loops surrounding the double-walled glomerular (Bowman’s) 
capsule and its’ attached renal 
tubule – subdivided into the 
proximal tubule, the loop (of 
Henle) and the distal tubule that 
connects the tubule to the collecting 
duct that flows into the renal 
papilla. 
The glomerular capsule is a highly 
specialized structure containing the 
glomerular filter, whose main 
function is to filter blood plasma to 
produce glomerular filtrate. To do 
this, the capillaries passing into the 
glomerulus are lined by specialized 
endothelial cells, adjoining a 
special basement membrane with 
both covered by specialized 
podocytes whose appendages 
encircle the arteriole. All three 
structures contribute to the filtration 
barrier, and about 20% of the 
afferent blood plasma filters into 
the capsule and into the adjoining 
tubule. Membrane permeability 
differs for the various constituents 
Figure 2. Nephron diagram. Source: Modifed from Anatomy & 
Physiology, Connexions Web site. http://cnx.org/content/col11496/1.6/ 
(Jun 19, 2013). Published under Creative Commons Attribution 3.0 
license. 
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of plasma, and is likely determined by the ultra-structure of the layers, the transmembrane 
pressure and the size (and potentially charge) of each plasma molecule.  
Thus, the composition of the filtered plasma (“primary urine”) entering the tubules is very 
different from urine and these differences are explained by mechanisms such as passive 
and active tubular reabsorption and secretion, enabling a tight control of the final urine 
composition. 
Glomerular filtration rate (GFR) describes the total volume of fluid filtered from the 
glomerular capillaries into the glomerular capsule per unit time and in all nephrons of an 
organism. GFR is usually assessed through a marker substance such as creatinine, but it 
should be kept in mind that results are then affected by the permeability of the membranes 
to the measured substance, as well as the net filtration pressure (stable over a wide range 
of blood pressures but not always), and any active reabsorption or secretion of the 
substance in the tubules.  The normal range of human GFR (normalized to body surface 
area) is 90-130 ml/min/1.73m
2
.  
1.1.3 Renal physiology 
The kidney participates in whole-body homeostasis, playing a central role for the 
maintenance of acid-base and fluid balances; regulation of sodium, potassium and other 
electrolytes; clearance of water-soluble waste products such as ammonia; the regulation of 
blood pressure; as well as recycling of glucose, amino acids and many other molecules. 
Having a low molecular-weight and dissociated from plasma proteins, water and many 
salts are freely filtered into the primary urine, from whence more than 99% is usually 
reabsorbed during tubular passage. As an example, sodium re-absorption occurs at several 
stages of the tubule and is an active trans-cellular transport from the tubular lumen to the 
interstitial fluid mediated by Na
+
/K
+
-ATPase pumps. Water is reabsorbed both passively 
by osmosis (dependent upon sodium reabsorption) and actively through water channels 
(aquaporins). These are specialized proteins that allow water but few other compounds to 
cross the cell membrane, and are usually synthesized ahead of time and stored in 
specialised intracellular vesicles ready to be used when needed (eg. dehydration). 
Aquaporins thus play an important role in maintaining water balance in both the short and 
long term. Other solutes, such as glucose, amino acids and bicarbonate are likewise 
passively and actively reabsorbed or secreted, often as a consequence of the sodium 
gradient and through co-transport and counter-transport mechanisms. 
The long-term maintenance of sodium homeostasis is of central importance to life, as 
sodium is the major osmolyte in extracellular water and thus a key regulator of cell shape, 
intravascular volume and blood pressure. A decrease in plasma volume or GFR triggers 
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renal juxtaglomerular cells to secrete renin, an enzyme that splits angiotensin I from 
angiotensinogen released by the liver. Angiotensin I is itself inactive, but is further 
cleaved into angiotensin II by angiotensin-converting enzyme (ACE). Angiotensin II in 
turn is a very potent regulator of blood pressure, acting both systemically on the 
vasculatures, locally in the renal arterioles and through stimulation of aldosterone release 
to promote the reabsorption of sodium and water in the kidney.  
Besides maintaining a healthy balance of ingested water and ions, the kidneys clear a 
variety of waste products from the blood. These include waste from protein catabolism 
and nucleic acid metabolism (nitrogenous compounds). Urea is the main vehicle for 
nitrogen waste including ammonia. It is primarily synthesized in the liver whence it 
travels in the blood to the kidneys and enters the urine. Urea additionally plays an 
important role in tubular water and ion reabsorption as it participates in a number of 
counter-current transporters. Another commonly encountered waste product is creatinine, 
it is also synthesized primarily in the liver through methylation of glycocyamine formed 
by muscle metabolism. As it is easy to measure and relatively independent of diet it is 
commonly used as a surrogate marker for or a means to estimate GFR. 
The kidneys also play an important role in maintaining the body’s pool of amino acids. 
This is achieved through both active tubular secretion and re-uptake of amino acids, de 
novo amino acid synthesis and lysosomal of plasma proteins leaking into the primary 
urine and endocytised by the tubular epithelium [1]. Thus, the kidney is the major site for 
removal of circulating glutamine (30% of daily disposal), proline (60%), citrulline 
(100%), S-adenosylhomocysteine (100%) and cysteinyl-glycine (90%), as well as the 
central source of circulating serine (100%), cysteine (100%), arginine (50%), tyrosine 
(50%) and lysine (5-20%). Daily around 300 mmol of free amino acids cross the 
glomerular filter, with about 98% reabsorbed [1-4].  
 
1.2 CHRONIC KIDNEY DISEASE/UREMIA 
1.2.1 Definition and classification 
Chronic kidney disease (CKD), also known as chronic renal disease, encompasses 
different pathophysiological processes associated with a progressive loss in kidney 
function over a period of months or years. To simplify communication and treatment 
studies, CKD has since about 15 years been defined as the persistent loss of at least one 
renal function for more than 3 months and divided into five stages based on eGFR and 
signs of structural damage to the renal filter (albuminuria). Stages 1-5 signify 
progressively worse renal health and declining estimated GFR (≥ 90 but eg. proteinuria; 
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60-89; 30-59; 15-29; <15 mL/min/1.73 m
2
, respectively). These cut-offs have been 
chosen somewhat arbitrarily but based on a dramatic and gradual increase in the risk of 
mortality and progression to end-stage renal disease (ESRD) [5]. As a comparison, 
normal ageing is associated with an observed decline in GFR from a peak value of around 
120 mL/min/1.73 m
2
 in young adults to a mean of 70 mL/min/1.73 m
2
 at age 70. 
Phenotypically, CKD stages 1 and 2 are usually not associated with overt symptoms of 
renal disease but carry an increased risk of mortality, hypertension and progressive kidney 
damage. At CKD stages 3 and 4 almost all organs are affected, with clinical 
complications of CKD including anemia, fatigability, hypertension, poor appetite, muscle 
catabolism, disorders in water and ion homeostasis, hyperlipidemia, acidosis, 
hypocalcemia, and osteoporosis. At stage 5 (ESRD), the accumulation of normally 
excreted toxins leads to marked disturbances of body function that usually necessitate 
renal replacement therapy for survival. Treatment options include hemodialysis (HD), 
peritoneal dialysis (PD), or kidney transplantation. 
1.2.2 Etiology and epidemiology  
Over the last 30 years CKD has become an important public health problem in most 
countries of the world [6, 7]. Partly as a result of increased obesity and diabetes, partly 
due to an increase in unhealthy living associated with increasing affluence, the incidence 
and prevalence of CKD is rising and some degree of the disease now affects more than 
10% of the general population in many countries [8-13]. Population survey data from the 
U.S.A. indicate a prevalence of more than 6% of adults for stage 1 and 2 CKD, 4.5% for 
stage 3 and 4 and perhaps 2% for stage 5 [8-13]. Common causes of CKD there include 
diabetic nephropathy (damage to the kidneys caused by diabetes; 30-40% of ESRD in the 
U.S.A.) [14, 15], hypertension [16-18], glomerulonephritis (an inflammation of the 
glomeruli or small blood vessels in the kidneys), IgA nephropathy (characterized by 
idiopathic IgA deposition in the glomeruli)[19, 20], urinary tract obstruction, and 
congenital diseases such as adult polycystic kidney disease. Acute kidney injury (AKI), 
also an important cause of CKD, is defined as a sudden decrease in kidney function that 
develops over a few hours or days, often as a complication to trauma or surgical 
interventions, and associated with a high morbidity and mortality risk. Of patients with 
AKI, 30%-70% have been reported to go on to develop some degree of CKD [21, 22]. 
Almost uniquely among the diseases of major body organs, the advances in science and 
therapy over the past decades have not greatly benefited CKD patients, who continue to 
have a rate of morbidity and  mortality far above the general population [23, 24]. Indeed, 
more than half of CKD patients are predicted to die before they reach stage 5, and the 
mortality risk of CKD is greatly increased at every stage. The rate of death in CKD in rich 
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nations divided by stage 3, 4, 5 has been estimated at 5, 10, and 15 times higher 
respectively than stage 1 and 2 CKD [23]. After starting dialysis, only about half of the 
patients will live beyond five years, mainly due to deaths from cardiovascular 
complications and infection [23, 24]. 
1.2.3 Symptoms and metabolic alterations in uremia 
Fatigue is an often reported early symptom of declining GFR, as is the loss of appetite, 
pruritus and mental acuity. With the gradual loss of filtration capacity (shrinking GFR), 
patients develop problems excreting salts and water. Oedema causes the swelling of the 
limbs. At more advanced stages of CKD, patients are at risk from acidosis (leading to 
muscle catabolism and imbalances in salts that can cause arrhythmia, muscle cramps and 
nerve tingling) as well as hyperkalemia (can give rise to deadly cardiac arrhythmias). 
Protein-energy malnutrition is another complication common in CKD patients, especially 
at lower GFRs. In patients before dialysis protein intake is restricted to reduce symptoms 
and preserve renal function, while with maintenance dialysis even a normal dietary 
protein and energy intake is often inadequate to the need, which is elevated also due to 
losses in the dialysate  [25].  
In general and regardless of etiology, CKD is associated with disturbances in nutritional 
homeostasis. This includes altered circulating and muscle amino acids profile [26], 
hyperglycemia or normoglycemia with apparent hyperinsulinemia [27], and disturbances 
in blood lipids (elevated triglyceride) and cholesterol/lipoproteins (high ApoB and low 
ApoA-bearing particles, very high Lp(a)) [28]. Circulating levels of insulin are elevated 
already early in the course of CKD and apparent insulin resistance (IR) correlates with 
GFR [29]. Interestingly, after the initiation of renal replacement therapy, insulin levels 
drop somewhat but are not completely normalized [30] (Table 1). 
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Table 1. Brief summary of studies investigating metabolism in CKD patients. 
Author Model system Findings in patients Ref 
Glucose and insulin 
Mulec H,  et al. 1998 Insulin-dependent 
diabetic nephropathy 
patients  
Hyperglycemia [31] 
Shinohara K, et al.2002 
 
CKD stage 5 
 
Insulin resistance (IR), a pathological situation 
in which cells fail to response to the normal 
actions of the hormone insulin 
[32] 
 
Chen J,  et al.2003 CKD stage 3-4 
without diabetes 
Hyperinsulinemia [27] 
Becker B, et al.2005 CKD stage 1-5 IR [33] 
Miyamoto T, et al.2011 CKD stage 5 
 
Hyperinsulinemia [34] 
Lipids 
Chan MK, et al. 1982 CKD stage 5 Hyperlipidemia, low HDL cholesterol [35] 
Cramp DG, et al. 1977 CKD patients without 
dialysis treatment 
High plasma VLDL-TG concentration [36] 
Batista MC, et al. 2004 CKD stages 3-4 
 
Low ApoA-I and high IDL and ApoB-100  [28] 
 Lee PH, et al. 2009 CKD stages 3-5 High serum TG level [37] 
Saland JM, et al. 2010 CKD stages 4-5 in 
children 
High TG, low HDL–C [38] 
Attman PO, et al. 2011 CKD stages 1-4  High ApoB and ApoC-III [39] 
Wang X, et al. 2012 CKD stage 5 High plasma TG, VLDL-TG, and VLDL-apoB-
100 concentrations 
[40] 
Amino acids 
Flügel-Link RM, et al.  
1983 
CKD stage 5 Low tyrosine, ratios of tyrosine to 
phenylalanine and valine to glycine 
[41] 
Bergström J, et al.  1990 CKD stage 5 Low  threonine, serine and valine [42] 
Divino Filho JC, et al.  
1997 
CKD stage 5 Low leucine, valine, phenylalanine, tyrosine [43] 
Valli A, et al.  2008 CKD stage 5 High S-adenosylhomocysteine and S-
adenosylhomocysteine 
[44] 
Fadel FI, et al.  2014 CKD stage 4-5 High plasma glutamine, homocysteine [45] 
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Underscoring the links between declining renal function and dysmetabolism, a renal 
transplantation with a well-functioning graft is associated with a marked reduction in all 
symptoms, a near normalization of metabolism (except in patients who develop IR due to 
cortisone medication), and a dramatic drop in the risk of cardiovascular disease and 
mortality [46, 47]. However, it must be noted that new but less dramatic risks emerge 
with the need for lifelong immunosuppressive therapy – including corticosteroids, 
azathioprine, mycophenolate sodium, mycophenolate mofetil, cyclosporine, belatacept, 
tacrolimus, everolimus and rapamycin [48-50].  
There is also a partial reversal of many of the symptoms listed above following the 
initiation of dialysis therapy, but the dramatically increased risk of morbidity and 
mortality remains unchanged or is even increased after initiation of dialysis [51]. 
Additionally, treatment with PD carries the risk of glucose overload due to absorption 
from the dialysate in the peritoneal cavity and studies have linked PD to the development 
of hyperglycemia and de novo diabetes [52, 53] in CKD patients. This treatment modality 
is also associated with higher circulating triglycerides (TG), low-density lipoprotein 
(LDL) cholesterol and Apo B levels as compared to those found in non-dialyzed patients 
with CKD stage 5 and HD patients [54]. Finally, it must be noted that the enumerated 
metabolic changes have not been linked to an increase in mortality risk in PD as 
compared to HD, which remains similarly high in both modalities. 
1.2.4 Uremic toxicity 
For unknown reasons, CKD is associated with systemic alterations in the functions of 
many organs that appear both quantitatively and qualitatively more linked to GFR decline 
than to the initial cause of renal damage. Due to the known purifying functions of the 
kidney and the fact that serum from renal patients can induce cellular dysfunction  in a 
range of tissues [55], it has been hypothesized that the retention of progressively larger 
amounts of normally excreted toxic compounds is the explanation. These unknown 
compounds are called uremic toxins, and the state of CKD is thus often referred to as 
uremia [56-58]. Uremic toxins are likely to include both soluble and insoluble molecules 
of many classes, presenting a variety of properties which makes their accurate 
classification extremely difficult. The European Uremic Toxin Work Group (EUTox) has 
been created within the European Society for Artificial Organs (ESAO) to discuss and 
analyze matters related to the identification, characterization, analytic determination, and 
evaluation of biologic activity of uremic retention solutes. They recently enumerated 90 
uremic toxins based on 857 publications between 1966 and 2002 [59], but also pointed 
out that newfound substances are added all the time [60-64].  
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The most common classification of uremic toxins is based on molecular weight. First, 
low-molecular-weight uremic toxins (<500 Da) that are soluble in water and thus easily 
removed by dialysis therapy; the EUTox listed 68 solutes in this group, including 
asymmetric dimethyl arginine (ADMA), creatinine, guanidine, oxalate, urea and uric acid 
[59]. Second, middle-molecular-weight molecules (> 500 Da) that are soluble in water; of 
which EUTox lists 22, including peptide hormones such as leptin, motilin and α1-acid 
glycoprotein. Third, protein-bound solutes, of which the EUTox lists 25; these have a 
high affinity for circulating transport proteins such as albumin, making them difficult to 
remove by dialysis. Their molecular weight is variable, but usually more than 500 Da, and 
the group includes advanced glycation end products (AGEs), indoxyl sulfate, phenolic 
compounds, and p-cresyl sulfate [59, 63-68]. Examples of uremic toxins according to this 
classification are given in Table 2, adapted from Vanholder et al.[59]. 
Urea and creatinine are classified as uremic toxins, but also function as biomarkers to 
estimate residual renal function. Importantly, studies have not linked either of these 
molecules to toxic effects, and it is likely that they are merely convenient markers of far 
more complex processes. Given the thousands of peptides found in healthy blood along 
with the hundreds of thousands of smaller metabolites, the EUTox classification is clearly 
outdated [69] and a new classification based on for example plasma proteomics or the 
impact of molecules on  major cellular pathways is needed. 
 
 
 
 
 
 
 
 
 
 
 
 
 10 
Table 2. Examples of types and sizes of different uremic toxic molecules.  
Low molecular-weight water-soluble toxins  Middle molecules Protein-bound 
1-methyladenosine  N2,N2 dimethylguanosine Adrenomedullin 2-methoxyresorcinol 
1-methylguanosine N4-acetylcytidine Atrial natriuretic peptide 3-deoxyglucosone 
1-methylinosine N6-methyladenosine β2-microglobulin CMPF  
ADMA N6threonylcarbamoyladenosine β-endorphin Fructoselysine 
α-keto-δ-guanidinovaleric acid Orotic acid Cholecystokinin Glyoxal 
α-N-acetylarginine Orotidine Clara cell protein (CC16) Hippuric acid 
Arab(in)itol Oxalate Complement factor D Homocysteine 
Argininic acid Phenylacetylglutamine Cystatin C Hydroquinone 
Benzylalcohol Pseudouridine Degranulation inhibiting protein I
c Indole-3-acetic acid 
β-guanidinopropionic acid SDMA Delta-sleep inducing peptide Indoxyl sulfate 
β-lipotropin Sorbitol Endothelin Kinurenine 
Creatine Taurocyamine Hyaluronic acid Kynurenic acid 
Creatinine Threitol Interleukin-1β Leptin 
Cytidine Thymine Interleukin-6 Melatonin 
Dimethylglycine Uracil κ-Ig light chain Methylglyoxal 
Erythritol Urea λ-Ig light chain Nε–(carboxymethyl)lysine 
γ-guanidinobutyric acid Uric acid Leptin ƿ-cresol 
Guanidine Uridine Methionine-enkephalin Pentosidine 
Guanidinoacetic acid Xanthine Neuropeptide Phenol 
Guanidonosuccinic acid Xanthosine Parathyroid hormone P-OHhippuric axid 
Hypoxanthine  Retinol-binding protein Putrescine 
Malondialdehyde  Tumor necrosis factor-α Quinolinic acid 
Mannitol   Retinol-binding protein 
Methylguanidine   Spermidine 
Myoinositol   Spermine 
  11 
1.3 THE HUMAN LIVER 
1.3.1 Liver anatomy 
The liver is the largest organ in the healthy human, normally weighting between 1.4–1.7 
kg. It is located in the upper right quadrant of the abdominal cavity, below the diaphragm 
and above the bowel. The liver receives an ample blood supply from two blood vessels, 
the hepatic artery that carries oxygen-rich blood from the aorta, and the portal vein which 
carries nutrients and other ingested substances from the intestines. The basic and 
functional units of the liver are the lobules, each of which is made up of millions of 
hepatocytes organized along with other cell types around a liver vein and a bile duct. 
Classically, the liver is grossly divided into six uneven lobes; a large right and a small left 
lobe at the anterior surface (diaphragmatic) and two additional lobes located between the 
right and left lobes shown from the inferior surface (visceral surface), the caudate and 
quadrate lobes. However, beside this classic anatomical division into lobes, a surgically 
relevant classification which divides the liver into eight segments based on blood supply 
as proposed by the French surgeon Claude Couinaud is often used (Figure 3).   
 
Figure 3. Couinaud classification system. Source: Polygon data is generated by Database Center for Life Science (DBCLS). 
Published under Creative Commons Attribution-Share Alike 2.1 Japan license. 
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1.3.2 Liver physiology  
With the intestinal efferent blood draining mainly through the portal vein, the liver plays a 
central role in metabolism. As the first organ to encounter the full range of absorbed 
molecules, the liver is a central site of detoxification, metabolism and storage. It plays 
vital roles in the homeostasis of carbohydrates, lipids, cholesterol, lipoproteins, proteins 
and amino acids, along with many vitamins and minerals.  
1.3.2.1 Glucose metabolism 
The liver maintains plasma glucose in a stable and narrow range through several 
complimentary mechanisms: after a meal, endogenous glucose release (from liver 
production and kidney reabsorption) decreases to a very low level due to pancreatic 
release of insulin, causing the liver to take up approximately 25-35% of the absorbed 
glucose and convert it to glycogen (glycogenesis) or fat (lipogenesis). During fasting this 
stored glycogen can easily be re-converted to glucose (glycogenolysis) and released, but  
the liver can also employ secondary sources such as lactate, pyruvate, amino acids and 
glycerol to manufacture new glucose (gluconeogenesis) for the same purpose.  
Gluconeogenesis is regulated mainly by transcriptional activation of the key enzymes 
phosphoenol pyruvate carboxykinase (PEPCK), fructose 1, 6-bisphosphatase and glucose 
6-phosphatase (G6Pase). Of these, the PEPCK promoter is well-known to be induced by 
circulating signals acting through second-messengers (glucagon, glucocorticoids, thyroid 
hormone) [70] as well as by transcription factors such as FoxO1 and hepatocyte nuclear 
factor (HNF)-4α. Peroxisome proliferator-activated receptor gamma coactivator 1-α 
(PGC-1α/PPARGC1A) acts as a master regulator and directly binds to HNF-4α or FoxO1 
to regulated their interaction with target genes [71] (Figure 4). Normally, insulin 
suppresses PEPCK and G6Pase gene expression via the second-messenger 
phosphatidylinositol 3-kinase (PI 3-kinase) pathway [72]. Of note, interleukin (IL)-6, a 
major activator of signal transducer and activator of transcription (STAT)-3, has been 
reported to markedly reduce PEPCK and G6Pase gene expression [73, 74].  
1.3.2.2 Lipid homeostasis 
The liver plays key roles in several pathways involving lipid metabolism. It is a key 
determinant of metabolism of fatty acids, lipoprotein turnover and release, as well as 
cholesterol synthesis and degradation.  In the exogenous pathway, dietary fats are 
emulsified and hydrolyzed by bile acids in the intestinal lumen, from whence they are 
then absorbed by enterocytes and packed into nascent chylomicrons (NCs) that enter the 
enterohepatic circulation via the lymphatic system [75].  
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At first bearing ApoA-I and ApoA-IV, the NC matures through interaction with HDL and 
thus aquires ApoC-II and ApoE as well as the ability to activate lipoprotein lipase (LPL), 
which catalyzes the hydrolysis of chylomicron TG into free fatty acids and glycerol [76]. 
Most of fatty acids are normally transported in this manner to either myocytes where they 
are used for energy production or else into adipocytes for energy storage. The 
chylomicron remnant then continues to the liver whence it is cleared through interaction 
with the LDL receptor, LDL receptor-related protein (LRP) and scavenger receptor B-1 
(SCARB1).   
The liver can also synthesize TG de novo from free fatty acids and glycerol.  In the 
endogenous pathway, these are combined with cholesteryl esters and ApoB-100 to form 
very low density lipoprotein (VLDL), which is able to transport its’ cargo to the periphery 
as described above. Excess cholesterol is transported from the periphery in HDL to the 
liver. 
Thus, fatty acids in the liver derive from either endogenous lipogenesis, direct uptake in 
the gut or lipolysis and transport from storage tissues such as adipocytes. Free fatty acids 
in the blood, for example bound to albumin, may also be taken up by hepatocytes through 
transport proteins such as fatty acid binding protein (FABP). Regardless of the substrate 
source, hepatic fatty acids synthesis is catalyzed by two key enzymes, acetyl-CoA 
carboxylase (ACC) and fatty acid synthase (FAS), both of which are regulated by the 
transcription factors sterol regulatory element-binding protein(SREBP)-1c and 
carbohydrate-responsive element binding protein (ChREBP) [77] along with the nuclear 
receptors PPARα and  liver X receptor (LXR)-α [78-80]. Likewise, TG is generated by 
the enzyme diacylglycerol acyltransferase (DGAT) under the control of C/EBPα or 
PPARγ [81, 82].  
Finally, oxidation of fatty acids in the liver occurs in mitochondria, peroxisomes and 
microsomes depending on the chain length. Carnitine palmitoyltransferase  (CPT)-1 is the 
rate-limiting step of mitochondrial fatty acid β-oxidation, through its' control of  long-
chain acyl-CoA transport across the mitochondrial membrane [83] (Figure 4).  
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Figure 4. Glucose and lipid metabolism in hepatocytes. 
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1.3.2.3 Cholesterol and bile acids homeostasis 
Cholesterol is a critical component of the cell membrane, steroid hormones and vitamin 
D. It also functions as a signaling molecule that interacts with several nuclear hormone 
receptors. About 20–25% of the total daily cholesterol production occurs in the liver. This 
synthesis begins when two-carbon acetate groups from acetyl-CoA condense to form 
acetoacetyl-CoA, which is then converted into 3-hydroxy-3-methylglutaryl CoA (HMG-
CoA). Next, HMG-CoA is irreversibly converted into mevalonate by HMG-CoA 
reductase (HMGCR), the rate-limiting enzyme of this pathway. Cholesterol is also a 
precursor for bile acids. Primary bile acids are exclusively synthesized in the liver, from 
where they are mainly released to the bile but also to the bloodstream. As many bile acid 
metabolites are cytotoxic synthesis, storage and release are tightly controlled, mainly 
through transcription of the rate-limiting enzyme in bile acid synthesis,  cholesterol 7a-
hydroxylase (CYP7A1) [84] . 
1.3.2.4 Amino acids and proteins 
Most of the plasma proteins found abundantly in healthy plasma are synthesized 
exclusively in the liver. These include as albumin, α-1-microglobulin and α-1-antitrypsin, 
as well as most coagulation factors and the inhibitor of calcium complex formation, 
AHSG. The hepatocytes are also the primary site of production for substrates of protein 
metabolism including non-essential amino acids, deamination and transamination 
reactions, the removal of excess ammonia via the urea cycle, and the production of ketone 
bodies during prolonged starvation. 
Ammonia is a waste product of oxidative de-amination reactions. Due to its’ toxicity at 
even low concentrations, it is rapidly and effectively removed from the body in the urea 
cycle (also named ornithine cycle). This sequence of reactions mediates the conversion of 
ammonia into non-toxic urea through a series of biochemical reactions that all occur in 
the liver (Figure 5). Urea is subsequently released into the bloodstream to be passively 
and actively secreted by the kidneys. 
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As shown in Figure 5, urea 
synthesis entails NH3
+
, HCO3
−
 
and ATP combining to form 
carbamyl-phosphate, which in 
turn reacts with ornithine to 
form citrulline. The last 
reaction occurs in the 
mitochondria, were it is 
catalyzed by ornithine 
transcarbamylase (OTC). 
Citrulline is then released back 
into the cytosol to react with 
aspartate to form 
argininosuccinate, a reaction 
catalysed by argininosuccinate 
synthetase (AS). Next, 
argininosuccinate is cleaved to 
form fumarate and arginine by 
argininosuccinate lyase (AL). 
Fumarate is oxidized in the 
tricarboxylic acid (TCA) cycle, 
while arginine is cleaved to 
form ornithine and urea.  Urea 
is then dissolved into the blood 
stream and transported to the 
kidneys. There, it is passively 
filtered through the glomerular 
filter as well as actively 
excreted into the tubular 
epithelium. Interestingly, these 
same renal cells are also involved in arginine synthesis and reabsorption and both AS and 
AL are highly expressed in the kidneys  [85]. 
1.3.2.5 Xenobiotics 
Finally, the liver metabolizes many xenobiotic compounds. Often this involves 
biotransformation of chemical structures to remove biological activity and increase water 
solubility, while final clearance is often through the kidneys. For simplicity, the reactions 
involved are often divided into three phases: Phase I (modification), Phase II 
(conjugation), and Phase III (excretion). Phase I reactions occur mainly in the liver but 
Figure 5. The reactions of the urea cycle.  
Source: WikiMedia. Published under Creative Commons Attribution 3.0 license. 
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also in other tissue, including the kidneys, lungs, gastrointestinal epithelium and the skin. 
A variety of enzymes catalyze Phase I reactions, including cytochrome P (CYP) 450 
oxidases CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. The purpose of these 
reactions is to convert xenobiotics to more water soluble metabolites by unmasking or 
inserting a polar group, such as -OH, -SH, or -NH2. In Phase II, the modified compounds 
are conjugated with charged molecules such as glutathione or sulfate to form yet more 
polar groups, for example carboxyl (-COOH), hydroxyl (-OH), amino (NH2) and 
sulfhydryl (-SH) groups. A large number of enzymes may be involved but the most well 
studied is glutathione S-transferase [86]. These reactions increase water solubility. 
Finally, in Phase III the conjugated xenobiotics are further deactivated through the 
addition of acetylated conjugates. This renders the molecule accessible for members of 
the multidrug resistance protein (Mrp) family, a member of the ATP-binding cassette 
transporters superfamily that aids the removal of the molecule to the circulation [87-89].  
1.3.3 Liver resection 
Liver resection, also referred to as hepatectomy, is the surgical removal of a portion or all 
of the liver, often to remove a benign (eg. hepatocellular adenoma, hepatic hemangioma 
and focal nodular hyperplasia) or malignant (hepatocellular cancer) growth. Liver 
resection may also be performed in cases of metastasis from non-hepatic cancers to the 
liver (eg. colorectal cancer). It is reported that around 10-25% of colorectal cancer 
patients have metastatic liver disease [90-92]. Finally, in orthotopic liver transplantation 
surgery the recipient’s liver is removed and replaced by a donor liver from a deceased 
donor, or parts of the liver from a living donor. The ex-planted liver tissue may be used 
immediately or stored for a short time in so-called University of Wisconsin preservation 
solution. Indeed, human hepatocytes have been isolated from liver tissue after storage for 
up to 48 h at 4°C at a similar yield, viability and plating efficiency as those isolated from 
fresh tissue [93]. 
 
1.4 HEPATOCYTES 
1.4.1 Hepatocyte structure and function  
Hepatocytes are the main functional cells of the liver, and are involved in all of the 
various metabolic, endocrine and secretory processes that take place there. They are also 
the site of synthesis of serum proteins such as albumin, most blood clotting factors, 
lipoproteins, bile salts and phospholipids. Hepatocytes, also called hepatic parenchymal 
cells, account for approximately 80% of the total liver volume and 60-65% of the total 
cell count. Functionally, the hepatocytes are arranged in hexagonal plates that anastomose 
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with one another, each intersected at right angles with a vein. Hepatocytes in situ are 
polygonal in shape, while their surfaces border either the sinusoids (sinusoidal face, 
location of the blood-flow to the central vein) or neighboring hepatocytes (lateral faces). 
Through the blood-filled sinusoids a variety of substances are transported. Additionally, 
the lateral faces of several hepatocytes, connected by tight junctions, form a bile 
canaliculi that collects newly released bile and delivers it into the bile ducts and ultimately 
to the gallbladder. Microvilli are abundantly present on the sinusoidal faces and greatly 
increase the cell surface area there, while they are only sparsely seen in the bile canaliculi.  
The remaining cells in the liver, called non-parenchymal cells (NPCs), include Kupffer 
cells, sinusoidal endothelial cells, stellate cells, cholangiocytes (epithelial cells) and 
intrahepatic lymphocytes. NPCs are thought to exert both positive and negative influence 
on hepatocyte proliferation and function [94], in addition to forming a physical barrier 
between hepatocytes and the blood circulating within the sinusoids [95] (Figure 6).    
 
                
Figure 6. Microscopic anatomy in liver.  Source: WikiMedia. Published under Creative Commons Generic 2.5 license. 
 
1.4.2 In vitro systems for hepatocyte studies 
Human primary hepatocytes in culture have been reported to be the most relevant cell 
culture system to study liver-specific molecular mechanisms of glucose, lipid and bile 
acids metabolism [96]. However, due to the scarcity of fresh human liver samples, 
complicated isolation procedures, short survival time and high costs involved in working 
with primary cultures, the human hepatoma cell lines HepG2 and HuH7 are frequently 
used instead. However, these hepatoma cell lines are derived from single donors and have 
spent a long time as immortalized cells in culture [96]. These phenotypic changes may 
lead to erroneous conclusions. For example, both HepG2 and HuH7 have been shown to 
lack expression and activity of certain CYP450 and Phase II detoxification enzymes 
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present in human hepatocytes [97-99]. HepG2 cells secrete bile acid precursors and 
unconjugated bile acids that are not found in adult humans, and are thus unsuited to the 
study of bile acids conjugation reactions and transport [100-103].  
Primary mouse or rat hepatocytes are also an alternative for in vitro liver research. They 
have been used in the few previous studies of uremic liver, but suffer from important 
limitations due to interspecies differences. Thus, many aspects of cholesterol and TG 
synthesis [104], CYP450 detoxification [105], gluconeogenesis [106-108], and 
apolipoprotein expression [109] are known to differ between man and rodent. However, it 
was rat livers that in 1969 were used by Berry and Friend [110] to develop the 
collagenase perfusion method still used to isolate viable hepatocytes. This discovery was 
the basis for later improvements and adaptions to isolate primary human hepatocytes 
[111-113]. Today, the two-step perfusion procedure used in our studies is the most 
common and widely accepted [114]. 
1.4.3 Human primary hepatocytes culture 
As described hepatocytes have an apical and a basal aspect, and attachment to an 
extracellular matrix (ECM) is necessary to maintain these ex vivo. Failure to attach or the 
lack of the right ECM components causes decreased cellular polarity accompanied by the 
loss of transcription of many liver-specific genes [115, 116]. Current protocols therefore 
attempt to monitor and maintain the polygonal shape and specific functions in cultures of 
isolated primary hepatocytes, most often through the coating of culture plates with rat tail 
collagen, sometimes with the addition of  Matrigel (a gelatinous protein mixture secreted 
by Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells) [117-119].  
Human hepatocytes cultured in this way exhibit a continuous monolayered growth with 
both constitutive and drug-induced microsomal CYP3A4 expression, the formation of bile 
canaliculi, active DNA synthesis and high expression levels of cytoskeletal mRNAs and 
proteins (actin, tubulin, cytokeratins, vinculin, alpha-actinin, and desmoplakin) [118, 120, 
121]. The effect of Matrigel on human primary hepatocytes in culture is disputed. 
Although human primary hepatocytes grown on a collagen and Matrigel substrate exhibit 
a clearer morphology of tight junctions, gap junction and bile canaliculi than do cells 
grown on collagen alone [118-120], no differences in the expression of P450 enzymes 
have been reported at high cell densities, while low density cells grown on collagen and 
Matrigel exhibited lower basal CYP3A4 expression than cells on collagen alone [118, 
122]. 
Using the above techniques, in vitro cultures of primary hepatocytes with stable 
phenotype can be reproducibly maintained for 10-14 days. Attempts have been made to 
extend culture times to several weeks [123-126], including through the addition of serum 
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or hepatocyte growth factor (HGF) and epidermal growth factor (EGF), adult human 
hepatocytes could survive at least 35 days with retain their basic phenotypical 
characteristics, such as liver specific proteins secretion (albumin, ApoA1 and ApoB100) 
and CYP1-4 family proteins expression [124], or by using collagen gel sandwich systems 
to keep cells up to 78 days, the polygonal morphology and high levels of albumin 
secretion were maintained throughout the culture period [123].  
 
1.5 BILE ACIDS  
In addition to their role in solubilizing lipids in the intestine, regulating cholesterol 
excretion and participating in the enterohepatic circulation, recent findings suggest that 
bile acids also act both locally and systemically to modulate multiple signaling pathways 
involved in the sensing and metabolism of lipids, glucose and energy [127, 128]. Impaired 
regulation and expression of bile acid synthesis and transporters may play a role in a wide 
range of human diseases, including fatty liver disease, diabetes, obesity and irritable 
bowel syndrome [129-131].  
1.5.1 Chemical composition 
Bile acids are water-soluble, amphipathic molecules synthesized from cholesterol in the 
liver in order to facilitate the uptake of lipophilic nutrients and regulate cholesterol 
homeostasis [127, 132]. Structurally, bile acids are composed of four rings of steroid 
structure, terminating in a five- or eight-carbon side-chain of a carboxylic acid [133]. The 
four rings are termed A, B, C, and D from left to right, with the D-ring always having one 
carbon less than the other three (Figure 7). The hydroxyl groups can be located up 
(termed β) or down (termed α). All bile acids have a 3-hydroxyl group which is derived 
from cholesterol [133].  
1.5.2 Bile acid synthesis 
The human bile acid pool consists of the primary bile acids chenodeoxycholic acid 
(CDCA) and cholic acid (CA) synthesized from cholesterol in the liver, along with the 
secondary bile acids - deoxycholic acid (DCA, from CA), lithocholic acid (LCA), 
isolithocholic acid (ILCA) [134] and allolithocholic acid (ALCA) [135] (all from CDCA) 
- created in the intestinal lumen through the actions of bacterial enzymes. Other vertebrate 
species have bile acids, but these have evolved differently along with the gut microbiota. 
Mainly, the differences are in the configuration of steroid nucleus and side-chains, 
including hyocholic acid in pigs [136], α- and β-muricholic acid (MCA) in rodents, and 
ursodeoxycholic acid (UDCA) in bears [137].  
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Also, even before the primary bile acids are secreted from the hepatocyte into the lumen 
of the bile canaliculi, more than 98% are conjugated via an amide bond at the terminal 
(C24) carboxyl group to one of the amino acids glycine or taurine. The resulting molecule 
is termed conjugated bile acid and the conjugation makes them more readily excretable 
into the bile and renders them less cytotoxic [138].  
The synthesis of bile acids involves a total of 17 individual enzymes that catalyze a 
complex array of reactions in the endoplasmic reticulum, mitochondria, cytosol and 
peroxisomes [137]. Synthesis takes place through one of two pathways, the classic and 
the alternative pathway. In the classic pathway of bile acid synthesis, which accounts for 
approximately 90% of total bile acid production, hydroxylation of cholesterol at the 7α 
position is the first step. This reaction is rate-limiting and catalyzed by CYP7A1 [139]. 
7α-hydroxycholesterol is then converted into 7α-hydroxy-4-cholesten-3-one (C4) by 3b-
hydroxy-D5-C27-steroid dehydroxylase, which in turn can be hydroxylated by sterol 12α-
hydroxylase (CYP8B1) to form CA or directly used to generate CDCA, and the CA to 
CDCA ratio is thus a marker of CYP8B1 function. In the alternative pathway, which 
accounts for less than 10% of the total bile acids produced under normal conditions, the 
C27 of cholesterol is oxidized in a reaction that is catalyzed by the mitochondrial enzyme 
sterol-27 hydroxylase (CYP27A1), followed by hydroxylation at the C-7 position by 
oxysterol 7α-hydroxylase (CYP7B1) to form oxidation products that are then converted to 
CDCA [140-143]. The major bile acid synthesis and conjugation are shown in Figure 7. 
 
 
Figure 7. Major primary and secondary bile acid synthesis and conjugation. 
Source: WikiMedia. Published under Creative Commons Attribution 3.0 license. 
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1.5.3 Bile acid transport 
Following conjugation, bile salts synthesized in the hepatocyte are secreted into the bile 
canaliculi whence they flow into the larger bile ducts and finally enter the gallbladder. At 
the canaliculi membrane of hepatocytes, the ATP-binding cassette (ABC) transporter 
family member bile salt export pump (BSEP) is the major transport protein mediating 
efflux of bile salts, working against a concentration gradient with 100-1000 fold higher 
concentrations in the bile than in hepatocytes [144, 145]. In addition, Mrp2 and MDR1A 
also export bile acids into the bile, along with a range of organic anions such as bilirubin 
glucuronides, glutathione-S-conjugates and drugs [88, 146]. Hepatocytes also export bile 
acids into the systemic circulation through both OST-α and OST-β as well as Mrp3 and 
Mrp4 [147-150].  
Bile salts are stored in the gall bladder, and food intake stimulates gallbladder contraction 
to release bile into the duodenum. In the gut, bacteria modify the majority of bile salts to 
generate secondary bile acids. Around 95% of the resulting bile acids (modified and 
unmodified) are then reabsorbed in the ileum through the enterocyte apical sodium-
dependent bile transporter (ASBT) which is highly expressed in the brush border 
membrane. On the basolateral cell membrane of the same cells bile acids are re-exported 
into the blood stream (transcytosis) by organic solute transporters (OST)-α and -β, 
allowing their return to the liver via the portal circulation [148, 151]. There the recycled 
bile acids are taken up by hepatocytes using sodium (Na+)-taurocholate cotransporting 
polypeptide (NTCP) [152] and organic anion transporters (OATPs) such as OAT1B1 and 
OAT1B3 [153]. While NTCP is the primary conduit for conjugated bile acids, OATPs 
carry conjugated and unconjugated bile acids as well as cardiac glycosides, steroids, 
peptides etc [154-157].  
The entire process is referred to as the enterohepatic circulation of bile acids, and results 
in a loss of only about 5% of secreted bile acids into the feces. This fecal loss is 
compensated by de novo synthesis in the liver as described above. Of the reabsorbed bile 
acids, 90% are taken up by hepatocytes already on their first passage through the portal 
vein. Those that escape the liver and enter the systemic circulation are to some degree 
cleared by the kidney, as are bile acids exported by the hepatocytes directly into the 
bloodstream. However, healthy human urine contains only minute amounts of bile acids 
[158], as most bile acids filtered are reabsorbed in the renal proximal tubular epithelium, 
mainly through  its' expression of ASBT. In addition OST-α, -β and Mrp3 are expressed 
basolaterally in these cells, and are thought to mediate the re-export of bile acids back into 
the systemic circulation [159]. An overview of the circulation of bile acids is shown in 
Figure 8.  
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Figure 8. Circulation of bile acid.  T/G BA: tauro- or glycol-conjugated bile acids; S/U BA: 
sulphated  or glucuronidated bile acids. 
 24 
1.5.4 Bile acid regulation 
The amphipathic properties of bile acids make them able to integrate into cell membranes 
and lipid particles, a property that renders them cytotoxic at higher concentrations either 
intracellularly or extracellularly [160-162]. Thus the transcription of enzymes involved in 
synthesizing bile acids is tightly regulated, mainly by nuclear hormone receptors and 
other transcription factors that work together to maintain bile acid homeostasis [137]. In 
the hepatocytes, bile acids are natural ligands of the farnesoid X-receptor (FXR), a key 
nuclear receptor that activates multiple pathways of bile acid, glucose and lipid 
homeostasis as well as regulating certain inflammatory responses [127, 163-165]. Upon 
binding to bile acids, FXR induces the transcription of the short heterodimeric partner 
(SHP) gene, which in turn acts to suppress CYP7A1 [166, 167]. Likewise, NTCP has 
been reported to be regulated by bile acid-activated FXR via induction of SHP in primary 
rat hepatocytes, HepG2 and Cos cell lines [168]. Also, FXR has been shown to directly 
regulate OATP1B1 and OATP1B3 expression in Huh-7 or HepG2 cell line [169]. 
Hepatocytes nuclear factor-1α (HNF1α) has been reported to repress CYP27 
transcriptional activity by binding to its promoter [170].  
Many of the enzymes and transporter proteins that metabolize and transport bile acids are 
intimately involved in the processing of xenobiotics [171]. Perhaps for this reason, many 
of these proteins are regulated by three well-studied ligand-activated nuclear receptor 
transcription factors: pregnane X receptor (PXR), constitutive androstane receptor (CAR) 
and vitamin D (1, 25- dihydroxyvitamin D3) receptor (VDR). Thus treatment of human 
hepatocytes with a PXR ligand (rifampicin) has been shown to increase OATP1B1 and 
decreased OATP1B3 and BSEP mRNAs [172]. However, similar results were not seen 
for Mrp2 and 3, and later studies have indicated that their regulation is complex and may 
involve one or more of PXR, CAR, FXR and VDR [173-176]. Mrp4 expression increases 
after activation of CAR in both primary human hepatocytes and HepG2 cells [177].  
 
Data also support roles for PXR, CAR and VDR in the regulation of multiple genes 
involved in both Phase I and II reactions of drug metabolism, including CYP1A, CYP2B, 
CYP3A, sulfotransferases (SULTs) and UDP-glucuronosyltransferases (UGTs) [178]. 
Finally, OST-α and -β are both up-regulated by FXR in Huh7 and HepG2 cell lines, and 
this increase could be blocked through pre-treatment with FXR siRNA [177]. In 
summary, a role for NR in the regulation of bile acid synthesis and transports is evident,  
but the exact mechanisms and links to specific pathological conditions still need to be 
further elucidated [171].  
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1.6 HEPATIC METABOLISM IN UREMIA 
1.6.1 Glucose 
The liver plays a unique role in carbohydrate metabolism through its ability to take up and 
store glucose as glycogen, or to make new glucose through gluconeogenesis as required. 
In the postprandial state, blood glucose is taken up via the glucose transporter type 2 
(GLUT2) on hepatocytes, following immediately by either oxidization for the production 
of energy (ATP), glycolysis catalyzed by glucokinase or utilization for glycogen synthesis 
by glycogen synthase. Conversely, in the fasting state the liver generates glucose both 
through the breakdown of stored glycogen and de novo synthesis (gluconeogenesis).  
In 1910, Newbauter et al. [179] first described hyperglycemia in the setting of uremia. 
Since then abnormalities in carbohydrate metabolism in CKD patients have been reported 
by many investigators [180-182]. Abnormal results on an oral glucose tolerance test 
(OGTT) may occur in over 50% of individuals with CKD stages 3-5 [180, 183]. Despite 
this the vast majority of non-diabetic patients with uremia are euglycemic when sampled  
fasting, but many exhibit increased circulating insulin levels and an impaired glucose 
disposal rate on intake [29, 34, 184].The mechanisms underlying this impaired glucose 
metabolism have been studied by a few researchers, who have proposed causative factors 
including metabolic acidosis, toxic substance accumulation (eg. free fatty acids, 
antagonistic insulin hormones, pseudouridine, etc) or an increase in gluconeogenesis 
[184-186].  
Insulin is an anabolic hormone produced by β-cells in the pancreas. It is the qualitatively 
most important regulator of carbohydrate disposal in the postprandial state; it is also 
involved in lipid metabolism. Key effects of insulin include an increase of glucose storage 
as glycogen in muscles and in the liver, inhibition of glucose synthesis by the liver, and 
promotion of lipid storage as TG in adipose tissue. As noted, insulin levels are often 
elevated in the setting of uremia. The reasons are unknown, but may include a reduced 
clearance in the proximal tubules and increased sympathetic nerve activity [187, 188].   
In the 1980s, DeFronzo et al. described IR (separate from hyperglycemia) in CKD 
patients [29]. Following this report, several studies have used cellular and animal models 
to increase our understanding of the mechanisms but key facts are still missing.  Friedman 
et al. [189] studied CKD patients using hyperinsulinemic euglycemic clamps and reported 
that the increase in insulin-stimulated glucose transport is significantly reduced (by 50%) 
in muscles of these patients as compared to controls. Subsequent studies have shown 
decreased tyrosine phosphorylation of IRS-1, abnormalities of PI3K signaling, as well as 
a decreased serine phosphorylation of downstream PKB/Akt in rodent CKD models [190, 
191]. 
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Regarding hepatic glucose production in uremic patients, there is no consensus.  Friedman 
et al. [189] and DeFronzo, RA [192] both found no effect of uremia on hepatic glucose 
production using hyperinsulinemic euglycemic clamps, and studies of liver slices from 
uremic rats likewise uncovered no defects in hepatic glycogen metabolism [193]. 
However, Schmitz et al. [194] found that hepatic glucose production was reduced by 
hyperglycemia in controls but not in uremic patients, indicated an impaired suppression  
in these patients. Likewise, cultured primary rat hepatocytes have been reported to exhibit 
a blunted response in glucogenesis upon insulin stimulation [195]. More recently, 11β-
hydroxysteroid dehydrogenase type 1 (11βHSD1), a determinant of intracellular cortisone 
signaling, was found to promote IR in the livers of uremic in mice, leading to increased 
hepatic gluconeogenesis and lipogenesis [196].  
There are also data that link the accumulation of specific uremic toxins to dysmetabolism 
of glucose and lipids. Urea (putatively by inducing oxidative stress) [197], ADMA [198] 
and uric acid [199] have all been reported to associate with IR in CKD patients.  Of 
special interest, P-cresyl sulfate (a protein-bound uremic toxin) was recently shown to 
directly alter insulin signaling through activation of the extracellular signal-regulated 
kinases (ERK1/2) [200]. Clearly, future studies are needed to better characterize the 
nature, consequences and causes of IR in CKD. 
1.6.2 Lipids and cholesterol 
Dyslipidemia – especially an elevated TG, a reduced HDL and an increased VLDL 
concentration [34, 201] - is common in later-stage CKD, and not only together with 
proteinuria. Elevated blood cholesterol and TG have also been linked to an increased risk 
of CVD in CKD patients at both the pre-dialytic and dialytic stage [202]. Despite this 
association and the relationship between GFR and dyslipidemia [201], relative few studies 
have examined the role of hepatic lipid metabolism in the setting of uremia.  
In 1999, Vaziri ND et al. [203] found down-regulation of hepatic Apo A-I gene 
expression in 5/6 nephrectomized rats, a finding consistent with the known decrease in 
plasma Apo A-I concentration in CKD patients. Han et al. [204] used a rat model of the 
nephrotic syndrome (characterized by proteinuria without reduced GFR, 
hypercholesterolemia and hypertriglyceridemia) to report increased hepatic SREBP-1, 
LXR α/β, FAS, ACC and HMG-CoA-reductase, as well as reduced CPT and L-FABP, on 
protein level. They suggested that increased hepatic fatty acid production and reduced 
fatty acid uptake by the liver may contribute to hypertriglyceridemia in the nephrotic 
syndrome. Kyubok et al. [205] reported a similar result in 5/6 nephrectomized rats, and 
suggested a ChREBP-mediated up-regulation of lipogenic enzymes (FAS, ACC) and 
downregulation of PPARα-regulated fatty acid oxidation (CPT-1A) and DGAT. Wang X 
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et al. [40] found the secretion rates of VLDL-TG and VLDL-apoB-100 were not changed 
between CKD patients and healthy controls, the hypertriglyceridemia in patients was 
associated with the impaired plasma clearance. Finally, recently Stegmayr et al. [206] 
found that the administration of heparin anticoagulation to HD patients promptly resulted 
in a release of both lipoprotein and hepatic lipase to the blood.  They hypothesized that 
liver loss of these enzymes may result in a transient uptake deficiency engendering 
hypertriglyceridemia.  
In another recent study, Ananda et al. [196] reported elevations in TG, total cholesterol 
and non-esterified fatty acids in uremic rats which also had high hepatic expression of 
ACC, FAS, SREBP1c, HMGCR and 11βHSD1. They suggested an increase in de novo 
lipogenesis and cholesterol synthesis in the liver and showed that inhibition of 11βHSD1 
resulted in an improvement of dyslipidemia, suppressed hepatic gluconeogenesis and 
improved systemic insulin sensitivity.  
1.6.3 Alterations in xenobiotic metabolism  
CKD patients are often heavily medicated, while reduced renal function is well-known as 
a risk factor for adverse drug reactions [207-209]. Over 90% of common drugs are 
metabolized by CYP enzymes in the liver, whence they exit to be transported as inactive, 
water soluble compounds and excreted in the urine. In CKD, even without liver disease, 
drug clearance is impaired in proportion to the reduction in GFR [210]. This appears to 
primarily be the result of impaired hepatic CYP450 reactions [211], but is likely also 
affected by factors such as the decrease in plasma protein to bind drugs, reduced hepatic 
conjugation reactions (primarily glucuronidation and acetylation [212-215]) and the 
accumulation of bioactive metabolites destined for renal clearance that may exhort feed-
back inhibition.  
In animal models of uremia, protein levels of several P450 members including CYP2C6, 
CYP2C11, and CYP3A2 are all reduced along with their activities. Levels of hepatic 
CYP3A are also low [216, 217]. In addition, CKD has been associated with reduced 
hepatic expression of OATP transporters involved in drug absorption [218]. For example, 
a decrease in OATP2 expression was induced in primary rat hepatocytes after treatment 
with sera from 5/6 nephrectomized rats [218]. Likewise, sera from ESRD patients reduced 
mRNA levels of OATP1B1 and 2B1 in Hep3B cells as compared with healthy serum 
[219]. Moreover an in vivo study found an impaired rate of hepatic xenobiotic uptake 
(approximately 20% lower) in 5/6th nephrectomized as compared to control rats, 
consistent with the previously reported finds of OATP downregulation [220]. In another 
study, primary rat hepatocytes exposed to uremic serum decreased CYP2C and 3A on 
both mRNA and protein levels as compared to those exposed to healthy serum [217]. The 
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fractionation of these sera revealed that the greatest decrease occurred with cell exposure 
to the 10-15 kDa fraction [221] . 
Specific uremic toxins have also been reported to directly inhibit CYP metabolism in 
vitro. A combination of the four uremic toxins benzyl alcohol, p-cresol, indoxyl sulfate 
and  hippuric acid co-incubated with human liver microsomes resulted in a decrease of 
more than 50% in the activities of CYP1A2, CYP2C9, CYP2E1, CYP3A4, UGT1A1, 
UGT1A9 and UGT2B7. P-cresol was found to be the most potent individual inhibitor of 
the four [222]. Volpe et al. In a similar study showed that clinically relevant 
concentrations of CMPF, hippuric acid and p-cresol inhibit CYP3A4 metabolism in 
human liver microsomes [223]. Another study combined CMPF, 3-indoxyl sulfate, 
indole-3-acetic acid and hippuric acid and also reported a decrease in CYP3A4 mRNA for 
the four together but not when tested one by one. The authors speculate that this may 
indicate a cooperative mechanism of action for these uremic toxins [224].  
 
1.7 FIBROBLAST GROWTH FACTOR (FGF) 19  
1.7.1 The FGF family 
The family of FGF is well known as regulators of developmental processes including 
differentiation, embryonic development, and angiogenesis [225]. Twenty-two human FGF 
family members are currently known. Of these, only FGF-19, 21 and 23 lack a heparin-
binding domain and instead utilize a co-receptor from the Klotho gene family to position 
the ligand in relation to its' cognate FGF receptor [226]. This reduced affinity for heparin 
is postulated to prevent these three FGFs from adhering to extracellular membranes, thus 
allowing them to circulate and reach distant sites of action in an endocrine manner. 
The study of FGF-19 in man has been slow to take off. Most of what we believe to be true 
for FGF-19 comes from studies of the mouse orthologue, Fgf-15. However, it should be 
noted that the homology between mouse Fgf-15 and human FGF-19 is only 40%, while 
most other FGF orthologues share more than 90% amino acid identity [227, 228]. 
Furthermore, Fgf-15 mRNA is mainly expressed in the ileum of adult mice while human 
FGF-19 mRNA has been reported to be expressed in significant quantities in fetal brain, 
skin, and retina, as well as in adult gallbladder, liver, kidney, spleen, heart, and leukocytes 
[229, 230]. Of the other two endocrine FGFs in humans, FGF21 is mainly expressed in 
pancreas and testis where it is regulated by PPARα, but it may also be found in the liver 
after fasting or under a ketogenic diet. Human FGF23 is mainly produced by osteocytes 
and osteoblasts and is regulated by VDR [231]. All three of these FGFs also exhibit large 
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individual variations, with median fasting levels (pg/mL) of 115 (47.4-349; FGF-19), 156 
(28.8-1844; FGF21), and 42.5 (21.2-87.0; FGF23) respectively [227, 232-234]. 
1.7.2 FGF-19 signaling and metabolism 
In humans, FGF-19 has been suggested to function as an enterohepatic signal exerting 
negative feed-back on the hepatic synthesis of bile acids. After a meal, bile acids released 
into the intestines stimulate the expression and/or release of FGF-19 by enterocytes, 
resulting in increased circulating levels. Holt et al. in 2003 treated human primary 
hepatocytes with the FXR agonists GW4064 and CDCA and demonstrated a large 
increase in FGF-19 mRNA expression, which were undetectable at baseline. The same 
group also uncovered a functional FXR responsive element in the FGF-19 promoter [235, 
236].  
For signal transduction FGF-19 probably requires the presence of both its receptor 
FGFR4 and the transmembrane protein β-Klotho, abundantly expressed in the liver. The 
Fgf-15-FGFR4-β-Klotho complex has been reported to be a strong suppressor of 
CYP7A1 gene expression, and consequently of bile acid synthesis in the liver [236, 237]. 
Study also shown that the FGF-19-FGFR4-β-Klotho complex activates the 
MAPK/ERK1/2 pathway in human primary hepatocytes, but the downstream mechanism 
that results in CYP7A1 inhibition is still unclear [238] while the levels of FGF-19 needed 
to suppress were  approximately 10-fold higher than those reported to occur in man [235, 
239]. However, clinical studies have confirmed a role for FGF-19 in regulation of bile 
acid synthesis in vivo. Lundasen et al. [240] found that humans exhibit a diurnal rhythm 
of FGF-19 secretion, with peaks appearing 90-120 min after a postprandial rise in serum 
bile acid levels and always followed by a decline in bile acid synthesis.  
In addition to the regulation of bile acid synthesis, researchers found that FGF-19 also 
plays a role in gallbladder filling [241] as well as putatively in glucose and lipid 
metabolism. Two studies have reported an increased metabolic rate following FGF-19 
administration to an obese mouse model, a change accompanied by decreased liver TG 
content and a lower circulating cholesterol level [242, 243]. Recent data also implicate 
mouse Fgf-15 signaling in regulation of a physiologically important, insulin-independent 
endocrine pathway that stimulates hepatic glycogen production and protein synthesis, but 
not lipogenesis [244]. However, in humans serum FGF-19 levels have been reported to 
vary independently of lipids [234]. Finally, in mice Fgf-15 can also reduce the 
phosphorylation of CREB, thereby inhibiting PGC-1α binding to G6pase and PEPCK, 
repressing gluconeogenesis [245].  
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1.7.3 FGF-19 in uremia 
Most cytokines and peptide hormones are elevated in CKD [246]. The molecular weight 
of FGF-19 is around 20 kDa, and hence circulating FGF-19 should have a relatively low 
sieving coefficient at the glomerular filter and a large proportion enters the renal tubules 
for endocytotic clearance. Indeed, few studies have reported FGF-19 in fasting humans 
(see above), while the presence of Fgf-15 in rat blood plasma remains unconfirmed [247]. 
In CKD only one previous report examining FGF-19 in the circulation exists. In a cross-
sectional study of 60 fasting chronic hemodialysis patients and 60 controls, Reiche et al.  
found approximately 1.5 times higher concentrations in patients, where FGF-19 levels 
correlated negatively with biomarkers of inflammation [248]. 
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2 AIMS 
 
The overall aim of this thesis was to investigate putative hepatic signals and processes that 
may contribute to the described metabolic complications of chronic renal disease. 
 
The specific aims of the included papers were: 
 To investigate postprandial FGF-19 response in CKD patients in relation to 
insulin, glucose and TG levels  (Paper I). 
 
 To characterize the key pathways known or suspected to mediate and regulate the 
metabolism of glucose and lipids in human hepatocytes under uremic and healthy 
conditions (Paper II). 
 
 To explore changes to bile acid metabolism pathways in human hepatocytes under 
uremic and healthy conditions and relate them to nuclear receptor and FGF-19 
(Paper III). 
 
 To assess physiological levels of FGF-19 and bile acids in the portal and systemic 
circulation (Paper IV). 
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3 METHODOLOGY  
3.1 ETHICS 
All studies were approved by the original ethics committee and informed consent was 
obtained from all patients.  The thesis in its entirety conforms to the declaration of 
Helsinki as amended. 
3.2 TISSUE DONORS 
3.2.1 Patients 
In Paper I, we enrolled ten non-diabetic CKD patients receiving maintenance 
hemodialysis (HD) since at least 3 months, thrice weekly and for at least 3.5 h per 
treatment. During the 8 weeks trial, 4 subjects dropped out (3 due to unrelated 
hospitalizations and one due to a failure to tolerate the test meal). Ten unrelated non-
diabetic healthy subject (HS) were recruited by advertisement to serve as the control 
group. One control dropped-out by choice. Exclusion criteria were age under 20 or over 
70 years, ongoing treatment for infection or inflammatory disease, mental illness, chronic 
bowel disease, a history of cholecystectomy and/or malabsorption and known liver 
disease. Following baseline assessment, each patient was treated with each one of N-
acetyl cysteine (NAC) (dosage 600 mg per os b.i.d. = 1200 mg daily), freeze-dried 
blueberries (MP865; dosage 240 mg per os b.i.d. = 480 mg daily) or lactose placebo 
(dosage 200 mg per os b.i.d. = 400 mg. daily) in a double-blinded manner and random 
order with a 7 days treatment followed by a 7 days washout repeated three times.  
At the end of each treatment period (day 7) and following an overnight fast of at least 8 
hours, each patient was given a standardized high fat (from cream), carbohydrate-rich 
(sucrose) meal (700 kcal/m
2
 of body surface area) followed by blood sampling at 6 time 
points over 4 h (see method below). The study design is illustrated in Figure 9.  
In Paper IV, 75 patients were enrolled from those undergoing hepatic surgery at the 
Transplantation Unit of the Karolinska University Hospital in Huddinge. These surgeries 
constituted liver transplantation, living donation or liver resection. Patients with hepatitis 
B or C were excluded. 
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During surgery, liver and gallbladder knife biopsies as well as bile from the gallbladder 
were collected. Portal and systemic (central venous and peripheral arterial) blood samples 
were taken as seen in Figure 10.  
  
Figure 10. Schematic illustration of where blood 
samples were taken during liver surgery. 
 
 
Figure 9. Illustration of study design used in Paper I. 
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3.2.2 Uremic sera 
For Paper II and Paper III, serum samples were collected from eight patients with 
severe CKD (GFR 9.4±1.6 mL/min/1.73 m
2
) and treated with maintenance HD since at 
least 3 months, thrice weekly and for at least 3.5 h per treatment. Also from eight age- and 
sex-matched controls (GFR >80 mL/min/1.73 m
2
) recruited by advertisement. Exclusion 
criteria were: 1) age under 40 or over 75 years; 2) diagnosed chronic disease in any organ 
other than the kidney; 3) ongoing immune-modulatory or other unconventional 
pharmacological therapy; and 4) an inability to give informed consent.  Pre-made 
standard vacuum tubes (Vacutainer®, Becton Dickinson) were used to draw venous blood 
from the arm. The blood was sedimented at room temperature for 20 min, then 
centrifuged at 2,000 X g for 10 min at 5° C.  The supernatant was immediately pipetted 
into clean polypropylene tubes in 0.5 mL aliquots and frozen at –70 °C. Pooled sera from 
8 healthy and 8 patients were prepared separately. 
Part of the sera was next dialyzed against DMEM over a 2 kDa molecular weight cut-off 
filter using Slide-A-Lyzer G2 (#7721, Thermo Fisher Scientific) run at +4° C for 24 h 
(1:100 v/v). The resulting filtrate was then frozen at -70° C for later use. 
3.2.3 Liver donors 
Freshly resected liver tissues were obtained between years 2012-2015 from patients 
undergoing surgery for metastatic cancer or from donor livers that could not be used for 
transplantation. Liver tissue was transported to the laboratory from the operation rooms in 
cold Eagle’s Minimum Essential Medium (EMEM) within a short time from 
devascularization. In some cases the tissue was kept in University of Wisconsin 
preservation solution at +4° C overnight. Donor information regarding age, sex and the 
reason for surgery is summarized in Table 3 below. 
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Table 3. Human liver donor demographics. 
Donor ID Age (yrs) Gender Diagnosis Viability 
HF171 68 Female Metastasis (small bowel cancer) 81% 
HF174 86 Male Metastasis (colorectal cancer) 70% 
HF175 78 Male Hepatocellular carcinoma 50% 
HF179 69 Female Metastasis (colorectal cancer) 65% 
HF180 16 Male Healthy donor 77% 
HF186 57 Male Metastasis (colorectal cancer) 77% 
HF187 42 Female Leiomyosarcoma 78% 
VF13 47 Female Cardiac arrest 75% 
HF195 45 Female Metastasis (colorectal cancer) 67% 
HF196 72 Male Metastasis (colorectal cancer) 79% 
HF202 69 Female Metastasis (colorectal cancer) 69% 
HF208 32 Female Cholangiocellular cancer 74% 
HF211 79 Male Metastasis (colorectal cancer) 75% 
HF214 70 Female Cholangiocellular cancer 74% 
HF217 73 Male Metastasis (colorectal cancer) 70% 
HF218 57 Female Metastasis (colorectal cancer) 84% 
HF244 48 Female Metastasis (colorectal cancer) 90% 
HF319 64 Female Alcoholic chirrosis, EX-plant 73% 
HF320 68 Male Metastasis (colorectal cancer) 69% 
HF321 53 Female Metastasis (colorectal cancer) 67% 
HF322 25 Female Metastasis (colorectal cancer) 85% 
HF356 74 Female Metastasis (colorectal cancer) 74% 
HF360 74 Male Metastasis (colorectal cancer) 74% 
HF361 68 Female Donor (cerebellar hemorrhage) 73% 
HF362 26 Female Progressive Familial Intrahepatic Cholestasis 71% 
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3.3 ISOLATION OF PRIMARY HUMAN HEPATOCYTES 
Hepatocyte isolation was performed in a two-step perfusion procedure as previously 
described by Strom et al [239]. Briefly, the liver tissue was first perfused using catheters 
sutured into the main hepatic vessels and connected to a peristaltic pump.  Hank’s 
balanced salt solution (HBSS) with 0.5 mM EGTA was used to remove calcium and 
irreversibly disrupt the desmosomal connections between cells, followed by a washing 
step with only HBSS. The liver tissue was then was perfused with 250 mg/L collagenase 
(Collagenase XI, Sigma) dissolved in EMEM until the tissue was completely digested 
(approximately 20 min). All perfusion solutions were preheated and maintained at 37
o
C to 
preserve enzyme activity. Next, the liver capsule was cut using scissors and the 
parenchymal tissue chopped in ice-cold medium to release the hepatocytes. These were 
isolated using filtration and washed three times by centrifugation at 50 g for 5 min to 
remove any remaining collagenase and non-parenchymal cells. The trypan blue test was 
used to calculate cell viability and concentrations before the cells were plated. 
3.4 CULTURE OF HUMAN PRIMARY HEPATOCYTES  
Viable cells were seeded onto collagen-coated  (collagen made in-house from rat tail 
[249])  6-well plates at a density of 1.5 million cells/ well and cultured under standard 
conditions in William’s E medium supplemented with HEPES (25 mM), glutamine (2 
mM), insulin (1.2 nM), dexamethasone (100 nM), amphotericin B (0.05 µg/mL) and 
gentamicin (0.05 mg/mL). Five percent FBS was added for the first 2 hours after seeding, 
thereafter serum-free medium was used until the experiments.  
Cells were cultured at 37 °C in a humidified atmosphere of 5% CO2:95% air and medium 
changed daily during the experiment (total time 5 days). Based on a dose- and time-
response analysis (Paper II & III), thus 5% sera and 24h incubation time was selected. 
Briefly, in this analysis primary human hepatocytes were treated with 0%, 5%, 10% or 
20% sera for 1h, 6h and 24h, followed by assessment of mRNA levels of G6PC, PCK1, 
CYP1A1, FGF-19 and CYP7A1. The lowest serum concentration giving the strongest 
response was chosen along with the culture time that yielded the greatest changes. For this 
and all subsequent experiments we added the test sera to the culture medium on day 4. 
Cells were harvested on day 5 for isolation of RNA and protein and medium was frozen 
for later analysis. In Paper II, insulin treatment was performed during 6 h before 
harvesting RNA and for 15 min before harvesting protein (Figure 11). Also in Paper III, 
some experiments entailed culturing cells with either CDCA or GW4064 for 24h before 
harvesting RNA and protein. Thus, sera treatment and FXR-agonist were added 
simultaneously. 
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Figure 11. Schematic diagram of the cell experiments. 
 
3.5 RNA ISOLATION AND REAL TIME PCR ANALYSIS 
Total RNA was isolated from harvested hepatocytes using TRIzol Reagent (#15596-018; 
Invitrogen) and according to the manufacturer’s instructions, and then stored at -70 oC. 
The RNA was quantified and quality assessed with a NanoDrop ND-100 
spectrophotometer. Concentration was determined at 260 nm and purity by 260/280 nm 
ratio. Reverse transcription was carried out using the High Capacity cDNA Reverse 
Transcription Kit with RNase Inhibitors (#4374966, Invitrogen). Real-time PCR assays of 
relative mRNA expression were performed using TaqMan Real Time PCR (StepOnePlus, 
Applied Biosystems). TaqMan PCR probes were bought from TaqMan Gene Expression 
Assays (Applied Biosystems) as described in Paper II, III and IV. Data were calculated 
by linearization of measured Ct values corrected by those of the housekeeping gene 
Cyclophillin A in the same cDNA preparation.  
3.6 GLUCOSE PRODUCTION MEASUREMENT  
Glucose production was measured as previously described [250, 251]. Briefly, primary 
human hepatocytes were washed with warm PBS to remove glucose. Cells were then pre-
treated with 100 nM in serum-free Dulbecco’s modified Eagles’ medium (DMEM) for 15 
min, followed by stimulation with cAMP (100 μM) and dexamethasone (50 nM) for 3 h 
in serum-free DMEM with or without gluconeogenic substrate (2 mM sodium pyruvate). 
Cell culture media was harvested and glucose concentration assessed by Konelab 20XT 
centrifugal analyser (Thermo Electron Corp.). The glucose concentration in each case was 
normalized to cellular protein concentrations. The total glucose production from both 
glycogenolysis and gluconeogenesis was measured in the presence of gluconeogenic 
substrate (sodium pyruvate, # 11360-039, Thermo Fisher Scientific), while 
glycogenolysis was measured in the absence of pyruvate.  Glucose production via 
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gluconeogenesis was calculated as the difference between total glucose production and 
glycogenolysis. 
3.7 WESTERN BLOT ANALYSIS  
Primary human hepatocytes were washed twice in ice-cold PBS, then lysed and stored at -
70° C. A Bio Rad protein assay kit (#500-0006, Bio Rad) was used to determine protein 
concentrations. After SDS-PAGE, proteins were transferred onto the nitrocellulose 
membranes using the iBlot dry blotting system (#IB23001, Thermo-Fisher Scientific) or 
using a   polyvinylidene difluoride (PVDF) membrane. Membranes were blocked with the 
StartingBlock blocking buffer (##37543, Thermo-Fisher Scientific) for 30 min at room 
temperature. The membranes were then incubated with the primary antibody overnight at 
4° C, and with the secondary antibody for 2 h at room temperature. The readout was 
detected using SuperSignal West Dura Extended Duration Substrate (#34075, Thermo-
Fisher Scientific) according to the manufacturer’s instructions, with the chemiluminescent 
signals captured by a Vilber Lourmat UV-instrument. Image J software (U.S. National 
Institutes of Health) was then used to quantify band intensity. 
Antibodies for blotting were purchased from: Akt2 Rabbit mAb (#3063, Cell Signaling  
Technology(CST)); pAkt (Ser473) rabbit mAb (#4060, CST); pAkt (Thr450) Rabbit mAb 
(#12178, CST); FoxO1Rabbit mAb (#2880, CST); pFoxO1 (Ser256) antibody (#9461, 
CST); FoxO3a Rabbit mAb (#12829, CST); pFoxO1 (Thr24)/FoxO3a(Thr32) antibody 
(#9464,CST); Pan-Actin Rabbit mAb (#8456, CST); anti-rabbit IgG HRP-linked 
secondary antibody (#7074, CST); anti-AKR1D1 (#ab113503; Abcam), anti-OSTA 
(#ab103442; Abcam),  anti-OST-beta (#ab121285; Abcam),  anti-CYP8B1 (# ab129845; 
Abcam),  anti-beta Tubulin (# ab179513; Abcam), anti-NTCP (#ab133670; Abcam), and 
anti-BSEP (#GTX102608; GeneTex). 
3.8 PHOSPHORYLATION PROFILING ASSAY 
In a subset of samples (Paper II), the Proteome Profiler Human Phosphokinase array 
(#ARY003, R&D Systems) was used to assess kinase phosphorylation at 43 well-
characterized sites linked to intracellular signaling and according to the manufacturers’ 
instructions. Briefly, proteins were lysed using the kit lysis buffer, and then incubated 
with the antibody-spotted membranes overnight at 4°C. Following repeated washing, the 
detection antibody cocktails were incubated with the membranes for 2 h at room 
temperature.  Phosphorylated kinases that bound to the membranes were visualized by 
streptavidin–HRP chemiluminescence using the Vilber Lourmat UV-instrument. 
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3.9 ENZYME-LINKED IMMUNOASSAYS (ELISA) 
The concentration of ApoB in the cell medium was measured using the Human ApoB 
ELISA kit (#3715-1HP-2; Mabtech), whereas total-, phospho (Ser612) - and phospho 
(panTyr)-IRS-1 were analyzed with PathScan IRS-1 sandwich ELISA kits (#7328, 
#7332C and #7133C; CST) according to the manufacturer’s instructions. 
3.10 LIPID STAINING 
Intracellular lipid accumulation was assessed using the LipidTOX Green neutral lipid 
stain (#H34475, Thermo-Fisher Scientific) according to the manufacturer’s instructions. 
Cells were fixed with 4% formaldehyde for 20 min at room temperature, washed three 
times with PBS, and then incubated with the dye for 40 min at room temperature. Nuclei 
were stained using NucBlue Live ReadyProbes reagent (# R37605, Thermo-Fisher 
Scientific). Stained tissues were visualized on an Olympus IX 71 inverted epi-
fluorescence microscope. 
3.11 LIPID EXTRACTION AND QUANTIFICATION 
Cells were washed twice with PBS then incubated with hexan: isopropanol (3:2) for 1 h at 
room temperature on an orbital shaker. After transfer into glass tubes, drying was 
performed under N2 at 40°C. The dissolved dried lipids were extracted in CHCl3 and 
dried under N2 at 40°C. A mixture of CHCl3 and 1% Tritox-X-100 was then added and 
the samples were evaporated under N2 at 40°C. The dried lipid extracts were dissolved in 
water and clarified by heating at 60°C. TG concentration was then assessed by a 
commercial colorimetric kit (#11730711216, Roche Diagnostics GmbH), with absorbance 
read at 492nm using a Tecan plate reader. The reading was normalized to total cell protein 
concentration. 
3.12 BILE ACIDS EXTRACTION AND ANALYSIS BY GC-MS 
Total bile acids (LCA, DCA, CDCA, CA and UDCA) were extracted from serum and bile 
as previously described [252]. Briefly, serum was mixed with deuterium-labelled internal 
standard (D4-CA, D2-CDCA, D4-DCA and D4-LCA) and hydrolyzed with 1M potassium 
chloride overnight at 120°C. Bile acids were extracted by basic ether extraction followed 
by acidic ether extraction, then washed until neutral with water. The extracted bile acids 
were methylated with trimethylsilyl diazomethane then derivatized using 
hexamethyldisilazane and trimethylchlorosilane in pyridine. Samples were quantified 
with GC-MS (6890 Network GC system/5973 Network mass selective detector, Agilent 
Technologies) and analyzed using the MassHunter Workstation software (Agilent 
Technologies).  
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3.13 BILE ACID EXTRACTION AND ANALYSIS BY HPLC-MS/MS 
To measure conjugated and free bile acids, serum and cell culture medium were processed 
according to a modified protocol initially described by Tagliacozzi et al [253]. Samples 
were mixed with internal standards consisting of D5-CA, D4- UDCA, D4-LCA, D4- TCA, 
D4- GCA D4-GUDCA, D4-GCDCA, D4-DCA and D4-GLCA. The mixture was 
centrifuged at 13 000 x g for 15 min and the upper phase was transferred to a glass 
centrifuge tube and evaporated under N2. The residue was dissolved in MeOH and the 
tubes rinsed with a solution containing 40% MeOH, 0.02% formic acid and 10 mM 
ammonium acetate. The sample solution was transferred to Water’s vials containing 3 
parts 100% MeOH and 1 part 40% MeOH, 0.02% formic acid and 10 mM ammonium 
acetate. A Waters LC-MS/MS Micromass Quattro Micro 2695, equipped with a C18 
reverse- phase column and ESI in negative mode was used for analysis. The result was 
evaluated with MassLynx software (Waters). 
3.14 RNA SCOPE 
RNAScope 2.0 kit and RNA probe (Hs-FGF-19, cat# 553981, Advanced Cell 
Diagnostics) were used to detect RNA expression in tissue sections by in situ 
hybridization. Briefly, liver and gallbladder tissues were fixed in formalin, dehydrated, 
paraffin embedded and sectioned onto glass slides. The sections were then baked at 60
o
C 
and deparaffinized before pretreatment, hybridization and amplification according to the 
manufacturer’s protocol. Next, signal was detected with 3, 3’-diaminobenzidine (DAB) 
and slides were counterstained with Gill’s Hematoxylin I (Sigma-Aldrich). Finally 
samples were dehydrated and mounted with Mountex (Histolab) before detection of FGF-
19 using an Olympus 1X71 microscope. The limit for background staining was 
determined as one dot per every ten cells according to the manufacturer’s guidelines. 
3.15 OTHER LABORATORY ANALYSIS 
Serum glucose, insulin, urea and total protein were evaluated using a Konelab 20XT 
centrifugal analyser (Thermo Electron Corp.). VLDL-TG and VLDL-total cholesterol in 
cell culture medium were measured by fast protein liquid chromatography (FPLC) as 
previously described [254].   
3.16 STATISTICAL ANALYSES 
Data are presented as mean ± SEM. The significance of differences between groups was 
tested using paired Student’s t-tests after log transformation, or one-way ANOVA as 
appropriate. Statistical significance was set at p<0.05. All statistical analysis was 
performed with GraphPad Prism 6.0 (GraphPad Software Inc). 
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4 RESULT AND DISCUSSION  
4.1 ALTERED POSTPRANDIAL FGF-19 RESPONSE IN CKD  
In Paper I, we investigated the links between time-dependent stimulated FGF-19 release 
and postprandial glucose, lipids, oxidative stress and inflammation in six CKD stage 5 
patients on maintenance HD. Following an overnight fast, HD patients and HS received a 
standardized fat- and carbohydrate-rich meal, followed by 7 days treatment with an 
antioxidant compound: NAC or MP865 (freeze-dried blueberries) as well as placebo 
(lactose) and the meal procedure was repeated. A randomized (3 treatments but random 
order) and double-blind design was used (Eudra Clinical Trial Number 2005-004403-12).  
The main finding of this paper was a delayed or blunted plasma FGF-19 response in CKD 
patients followed for 4 hours postprandially, with a significant improvement (but not 
normalization) seen following antioxidants therapy (NAC or MP865). This is an 
interesting observation that requires further investigation.  
N-acetyl cysteine is a derivative of the amino acid L-cysteine, and has previously been 
reported to attenuate indoxyl sulfate-induced cell proliferation and tissue factor 
expression of vascular smooth muscle cells in vitro [255], reduce endoplasmic reticulum 
stress in macrophages exposed to uremic albumin [256], and to retard the decline of renal 
function in CKD patients over shorter time periods [257].  
Meanwhile, MP865 (freeze-dried blueberries) contain at least the active ingredient 
anthocyanins. These polyphenols are found in a range of colored berries and are known to 
function in vitro as potent scavenger of oxygen radicals [258]. However, the exact role of 
this capacity in vivo remains unproven, and recent data also link anthocyanin to effects on 
mitochondria leading to a reduction in cytosolic cytochrome c and improved oxidative 
phosphorylation in ischemia-damaged mitochondria [259].  
As either of the two compounds positively affected patient FGF-19 response to the same 
degree (basal versus NAC: −0.28, SE = 0.11, P = 0.01; basal versus MP865: −0.23, SE = 
0.1, P = 0.03), one may speculate that their anti-oxidative properties may be involved. 
Indeed, CKD is well-known as a disease with a high burden of oxidative stress and in the 
study cohort we measured a high level of advanced oxidation protein products (AOPP) in 
the patients (although this value was unaffected by therapy and did not increase following 
the meal provocation).  
In Paper I we also found the area under the curve (AUC) of FGF-19 to correlate with the 
AUCs for C-peptide and insulin over the same time, but not those of TG or glucose 
(Figure 12). These data do not fit with the few previous reports suggesting a role for 
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FGF-15/19 as a postprandial regulator of hepatic lipid and glucose homeostasis. For 
example, knock-in of FGF-19 in mice led to increased basal metabolic rate and lower TG 
levels in the liver [242], with a similar result has also observed in mice treated with FGF-
19 [243]. When considering our data in relation to the earlier reports it must be kept in 
mind that our data were in humans.  
Another potential confounder when interpreting our data on FGF-19 in the post-prandial 
state of CKD patients (Paper I) is the possible delay in gastric emptying known to occur 
in this group [260]. However, our data does not support such a delay in emptying. As 
shown in Figure 12, blood glucose and insulin rose rapidly in both groups, suggesting 
uptake from the meal. Furthermore, in both groups TG rose within 120 min of the meal 
and continued to rise for the duration of the follow-up (LDL did not change significantly 
during the study [34]). Thus, our data suggests both a timely and normal absorption of 
glucose (which normally starts in the mouth but takes place mainly in the intestinal 
epithelium and during the first 30 minute postprandially [261]) and fat (which is 
dependent on bile acids in the small intestine and on intestinal epithelium transcytosis). 
Regarding insulin, the healthy subjects exhibited a transient and rapid peak that left 
concentrations back at baseline levels at 240 min. Meanwhile the patients exhibited a 
higher rise and longer duration in insulin, but were still able to maintain blood glucose 
levels that were approximately the same as those in the controls or slightly higher.  
 
Finally, regarding FGF-19, published studies of healthy subjects usually report a 
postprandial peak in serum levels 90-120 min after a postprandial rise in serum bile acids 
[240]. In Paper IV, bile acid and FGF-19 correlated strongly in both the portal vein and 
in the systemic circulation, but were not followed longitudinally. However, these patients 
were fasting and undergoing surgery so it is unclear if such longitudinal data would be 
comparable to these previous studies. In data not included in Paper I, we assessed plasma 
bile acids in all patients and controls only after the MP865 treatment period. As shown in 
Figure 13, in this analysis our control subjects had the expected response with a peak in 
plasma bile acid at 120 min and a subsequent rise in FGF-19. Patients meanwhile also 
exhibited a rise in bile acid approximately simultaneously, but their FGF-19 levels never 
rose convincingly at all. Taken together, our data suggests that reduced FGF-19 release by 
synthesizing cells is the most likely explanation for the observed reduction in circulating 
levels in CKD. 
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Figure 12. Postprandial level of  (A) FGF-19, (B) glucose, (C) insulin, (D) TG. Grouped by healthy 
subjects (HS) or CKD patients on hemodialysis (HD). 
 
 
 
Figure 13. Postprandial FGF-19 and bile acids following 7 days of MP865 therapy.  (A) FGF-19; (B) 
Total bile acids. Grouped by healthy subjects (HS) or CKD patients on hemodialysis (HD). 
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4.2 HEPATIC FGF-19 SIGNALING IS UNALTERED IN CKD  
Bile acids are known to induce enterocytes to produce and release FGF-19 into the portal 
circulation, whence it reaches the liver. There it likely binds to its’ receptor FGFR4 
through a stabilizing co-factor, β-klotho, as reviewed above. This FGF-19-FGFR4-β-
Klotho complex is believed to initiate a strong suppression of CYP7A1 through c-Jun N-
terminal kinase (JNK)-signaling [235-237]. Recently, FGF-19 was also described as a 
direct target of nuclear FXR, while a functional FXR responsive element has been 
described in FGF-19 promoter [235, 236].  
In Paper III we were unable to observe any differences in mRNA levels of the FGF-19, 
receptors FGFR4 and β-Klotho or of CYP7A1 between human primary hepatocytes 
treated with uremic or healthy sera (Figure 14). And there was also no difference in 
phosphorylation of the intracellular signaling molecules JNK (neither at amino acids 
T183/Y185 nor at T221/Y223) and c-Jun (at S63) (Paper II). This suggests that the 
altered FGF-19 signaling is not of hepatic origin in uremia, at least in vitro. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. The in vitro effects of healthy uremic sera on mRNA of key components of the FGF-19 
pathway with our without FXR agonism. (A FGF-19 signaling pathway; (B) FGF-19 mRNA expression 
after FXR agonists treatment; (C) CYP7A1 mRNA expression after FXR agonists treatment. Data are 
presented as mean ± SEM. * p < 0.05 
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Hypothesizing that FXR-signaling may be required for a robust FGF-19 response in vivo, 
we also investigated this pathway after pre-treatment with either the natural FXR-ligand 
CDCA or the synthetic agonist GW4064. Treatment with either agonist induced a rise in 
FGF-19 mRNA and a decrease in CYP7A1 mRNA as previously reported [235], but there 
were no differences between the sera treatment. We conclude that hepatic FGF-19 
production is neither increased nor inhibited by uremic sera in vitro, nor is FGFR4/β-
Klotho signaling disrupted.  As FGF-19 in vivo is highly expressed in gall bladder and 
circulating FGF-19 may originate from gall bladder epithelium, further studies of uremic 
bile are needed.   
 
4.3 CIRCULATING FGF-19 REFLECTS PORTAL CONCENTRATIONS  
To better understand the physiological role of FGF-19 in humans, we next assessed FGF-
19 and bile acid concentration in portal and systemic (peripheral arterial and central 
venous) blood and bile from 75 non-CKD patients undergoing liver surgery (Paper IV). 
As expected, both bile acid and insulin exhibited an obvious concentration gradient across 
the liver (portal vein compare to either arterial or peripheral venous blood). We found no 
such differences in FGF-19 concentrations (Figure 15A). Fasting before surgery may be a 
confounder as both FGF-19 and bile acid concentrations in blood have been reported to 
decrease during fasting [240], but as all subjects had measureable levels of bile acids and 
insulin we do not believe this to be an important explanation. We conclude that peripheral 
measurements of FGF-19 concentrations likely reflect also portal FGF-19 levels.  
In Paper IV FGF-19 mRNA was very low or undetectable in liver biopsies, but high in 
gallbladder samples. Conversely, mRNA of CYP7A1, FXR, FGFR4, KLB and SHP were 
all significantly more abundant in the liver than in the gallbladder. Using RNA scope in 
situ hybridization staining on these tissues, we found FGF-19 mRNA only in the 
epithelial cells of the gallbladder (Figure 16). While Fgf-15 is predominantly expressed 
in the ileum of mice [236], FGF-19 expression in humans has primarily been found in the  
gallbladder, with only low levels in the ileum [262]. Our data offers confirmation of the 
previous human study [262] and reporting 60-fold higher concentrations of FGF-19 in 
bile than in serum (Figure 15B). The origins of circulating FGF-19 and its physiological 
role remain unclear. We conclude that hepatic FGF-19 release is not a major contributor 
to circulating levels in non-CKD individuals (and likely not in CKD-patients either). 
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Figure 15. FGF-19 concentration in portal, systemic blood and bile. (A) FGF-19 concentration in blood 
(n=75) and (B) bile (n=54). Data are presented as median with IQR, with statistical comparisons performed 
by median regression with cluster robust standard errors. *** P<0.001, ns – not significant. 
 
 
Figure 16. FGF-19 mRNA 
expression in liver and 
gallbladder. Representative in 
situ hybridization staining of 
sections from (A-C) liver 
tissue positive for FGF-19, 
original magnification 400x, 
(D) Gallbladder, original 
magnification 200x, and (E-F) 
liver tissue negative for FGF-
19, original magnification 
200x. (G) FGF-19 expression 
from each specimen measured 
by qPCR.
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4.4 HEPATIC INSULIN RESISTANCE OCCURS IN CKD 
To explore insulin-mediated glucose metabolism in our in vitro uremic hepatocyte model, 
cells were isolated from liver tissue and then treated with 5% pooled sera from patients 
(uremic group) and healthy (group) subjects (Paper II).  
We found a marked increase in glucose production through gluconeogenesis in uremic 
cells as compared to healthy. In healthy cells, addition of supra-physiological 
concentrations of insulin returned gluconeogenesis to baseline levels but there was 
virtually no change in cells treated with uremic sera (Figure 17). 
At the same time, we observed an increase in mRNA levels of gluconeogenic genes 
PEPCK (PCK1), G6Pase (G6PC) and their upstream regulators PGC1α (PPARGC1A) 
and HNF4A. Moreover, Akt phosphorylation at S473 decreased following uremic sera 
treatment, whereas no differences were observed in pAkt T450, pFOXO1 S256, 
pFOXO3a T32, pIRS-1 pan-Tyr or pIRS-1 S612 (Figure 18). Taken together, we believe 
our data suggest that insulin resistance develops in hepatocytes following exposure to 
uremic sera. 
 
 
Figure 17. Increased glucose production via gluconeogenesis under uremic conditions.  Data are 
presented as mean ± SEM. * p<0.05, ** p < 0.01. 
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Figure 18. Effect of uremic sera on hepatic glucose metabolism genes.  mRNA expression of 
gluconeogenetic genes (A) PCK1; (B) G6PC; (C) PPARGC1A; (D) HNF4A. (E) western blot; (F) 
quantification of blot densities. Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01. 
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Insulin resistance has recently been reported to occur in cultured hepatocytes from uremic 
rats (5/6
th
 subtotal nephrectomy) [195] while an earlier study described a 25% to 45% 
decrease in gluconeogenesis in the livers of rats with renal failure [263]. However, 
another study of a similar rat model found gluconeogenesis to be increased and speculated 
that this was an adaptive response to glycogen depletion [263]. In patients, glucose uptake 
has been reported normal in the liver but reduced by 60% in the leg [263].   
Our data also addresses the mechanism(s) behind the observed insulin resistance, but 
offers no clear answer. Hepatocyte mRNA of HSD11B1 (11βHSD1), but not of 
HSD11B2 (11βHSD2), increased under uremic conditions. The HSDs are catalytic 
enzymes that regulate intra-cellular glucocorticoid production by converting cortisone 
into cortisol (HSD11B1) or back (HSD11B2) [196]. Our data on HSD11B1 are of interest 
partly due to the large observed differences in hepatocyte responses to cAMP and 
dexamethasone depending on whether they had been cultured with uremic sera or not 
(Figure 17). Dexamethasone is a synthetic glucocorticoid estimated to be 50 times more 
potent than cortisol. They are also of interest since a recent study [196] in a rat model of 
CKD reported an increase in HSD11B1 at both the mRNA, protein and activity levels 
which also correlated with increases in hepatic gluconeogenesis and lipogenesis. While 
glucocorticoids are well-known to induce gluconeogenic genes (including PEPCK and 
G6pase) at the transcriptional level, the exact mechanisms leading to elevated HSD11B1 
under uremic conditions remains to be determined. Also remaining to be performed are 
interventional experiments deigned to assess if the elevation in HSD11B1 is a causal 
factor or merely a reflection of such a factor. Our data offers some support for a direct 
mediating role by showing that uremic sera can increase phosphorylation of p53 at the 
p38-specific S15 and S46 sites in human hepatocytes. In HepG2 cells pro-inflammatory 
factors including TNFα can induce transcription of HSD11B1 via the p38 MAPK-
C/EBPβ signaling pathway [264].  
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4.5 UREMIC HEPATOCYTES ACCUMULATE LIPIDS  
Following exposure over 24 hours to 5% uremic sera, we found that our primary human 
hepatocytes accumulated both intracellular and extracellular lipids. Concentrations of 
VLDL-TG in the media rose (Paper II), while fluorescent staining revealed an 
intracellular lipid content that was 56% higher in cells treated with uremic sera. 
Furthermore, when intracellular lipids were extracted, we found these to be 49% higher in 
uremic cells (Figure 19). Clinically, VLDL is frequently elevated in the circulation of 
CKD patients, who also exhibit an altered plasma composition of lipoproteins comprising 
low HDL, low ApoA and high ApoB [28, 35, 39]. In our model ApoB mRNA increased 
in uremic sera-treated cells, but ApoB protein levels in the media did not. Apart from a 
lack of one or more substrates (including cholesterol), these results may also reflect a 
possible role of post-translational regulation of ApoB [265].  
Compared to cells cultured with healthy sera, uremic cells also exhibited higher mRNA 
levels of lipogenic genes such as SREBF1, FASN, ChREBP, DGAT1, and CIDEC. 
Unexpectedly the same was found for several genes involved in lipolysis (LIPC, PPARα, 
CPT1A, FABP1) and lipoprotein uptake (LDLR, LRP1). These results are different from 
a recent report of uremic rats [205], where CPT1A and DGAT were reported to be 
decreased.   
Patient data on TG production in CKD suggest high levels. For example, Cramp DG et al. 
[36] studied 13 CKD patients not yet on dialysis and found increased hepatic production 
of TG. Also, others [35, 266]  have found a high prevalence of hypertriglyceridemia. 
However, in Paper I, we found no difference in baseline TG between patients and 
controls. Thus, further studies are needed before we can complete know the mechanism of 
dyslipidemia in CKD.  
Ideally, lipid metabolism could be assessed by studying fresh biopsies and primary 
hepatocytes obtained from CKD patients. However, multiple reasons make such a 
sampling difficult. Thus, we are pleased that several aspects of lipid metabolism known to 
be altered in CKD patients were also disturbed in our model. These disturbances were 
seen already at a 1:20 dilution of uremic sera, and were not changed by prior dialysis of 
these. We hope that our model can be used to further elucidate pathways perturbed by 
CKD.  
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Figure 19. Intracellular lipid accumulation in uremic hepatocytes. Cells were treated with healthy (4A, 
4B) or uremic sera (4C, 4D), following fluorescence staining for neutral lipid and nucleus. Green 
fluorescence reveals neutral lipid droplets, whereas the blue are nuclei. Integrated densities for each 
treatment group are shown in (4E). Direct cell lipid extraction and quantification was also performed and the 
results are given in 4F. Scale bar is 50μm in a–d; inserts illustrate original magnification × 40. 
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4.6 FEW CHANGES IN BILE ACID METABOLISM IN CKD 
To evaluate circulating bile acids in CKD patients and to link these findings to bile acid 
metabolism, we preformed analyses of the primary human hepatocyte model using in 
vitro exposure to uremic sera (Paper III). Using GC-MS/MS, we were unable to see 
any differences between the bile acid content of the serum. However, using a highly 
sensitive method based on LC-MS/MS, we found that patient sera on average contain 
higher levels of tauro-conjugated BA and higher levels of sulphated-LCA, as well as a 
higher proportion of easily soluble trihydroxy- bile acid forms. Analyzing cell culture 
media before and after experiments, we found no differences in primary bile acid content 
although concentrations were in general very low. 
At mRNA and protein level, we were also unable to detect any differences in key bile 
acid synthesizing enzymes, including CYP7A1, CYPB81, CYP27A1 and AKR1D1. 
However, several transporters implicated in bile acid shunting were higher in cells treated 
with uremic sera. These included NTCP, OST-α, and OST-β while OATP1B3 levels 
decreased. Our results thus confirm a recent report of similar findings in uremic rats 
[267].  To elucidate if the changes in bile acid transport genes could be physiological, we 
treated cells with two FXR-agonists, CDCA and GW4064. As expected, FXR-controlled 
genes were markedly induced in both groups, including SHP, OST- α, and OST-β while 
CYP7A1 decreased. Comparing the two sera groups, uremic sera-treated cells had a 
significantly higher increase in SHP and OST- α after both CDCA and GW4064 
treatment, as well as in OST-β under CDCA treatment. We conclude that central elements 
regulating the synthesis and release of bile acids appear to be unchanged in cells exposed 
to uremic sera. The observed increase in organic solute transporters' mRNA before and 
after FXR agonist may or may not be of relevance. We speculate that it may reflect a 
general increase in cellular stress in the uremic group, as a recent study [268] found that 
the nuclear receptors FXR and HIF-1α bind in close proximity to the OST-α gene 
promoter and produced synergistic effects on OST-α expression. Also, ammonia was 
recently shown to induce a normoxic accumulation of HIF1α in vitro[269], which may be 
one factor linking uremic toxicity to HIF-priming of target genes and a later accentuated 
response to FXR agonist. 
Finally, we investigated mRNAs of hepatic nuclear receptors after sera treatments. Our 
results showed significantly changes in uremic treated cells, but not in healthy cells. For 
example, mRNA of FXR, SHP and CAR increased while VDR mRNA decreased. No 
differences at the mRNA level were found for PXR, HNF-1α or AHR. Besides 
demonstrating the general nature of the metabolic disturbances induced by uremic sera, 
the above data are also of interest when designing future studies to elucidate the potential 
causes of dysmetabolism in uremic hepatocytes. Several nuclear receptors are thought to 
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interact directly with bile acids to modulate hepatocyte metabolism, including FXR, PXR, 
CAR and VDR [270-272]. Indeed, as reviewed above FXR is thought to be a key 
regulator of bile acid synthesis, CAR and PXR were reported to function as the 
xenobiotic-sensing receptors [273]. Recently, CAR was also reported to directly or 
indirectly regulate the expression of 11HSDB1 (which is also induced by 7-oxo-LCA) 
[274]. As we found elevated 11HSDB1 mRNA in our uremic hepatocytes along with 
enhanced glucocorticoid responses, IR (putatively induced by increased glucocorticoid 
signaling ) and higher levels of hydroxylated bile acid (another putative target of 
11HSDB1 [275]) it seems natural to design experiments to look at CAR-mediated 11β -
HSD1 signaling , downstream targets and a hypothetical interaction of CAR with one or 
more uremic toxins. 
 
 
Figure 20. mRNA expression in hepatocytes exposed to healthy and uremic sera. (A) Genes involved in 
bile acid synthesis; (B) Genes involved in bile acid transporter; (C) Genes of xenobiotic-metabolizing 
enzymes; (D) Nuclear receptors genes. Data are presented as means ± SEM; * p < 0.05; ** p < 0.01. 
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5 GENERAL CONCLUSIONS  
 
 Peripheral blood level of FGF-19 likely reflect portal FGF-19 concentration in the 
portal vein. 
 
 
 Advanced CKD may be associated with a blunted postprandial FGF-19 response 
that is partially normalised following 7 days of either one of the anti-oxidative 
treatments N-acetyl cysteine or freeze-dried blueberries. 
 
 
 In the liver, FGF-19 production appears to be neither increased nor inhibited by 
uremic sera in vitro, nor is FGFR4/β-Klotho signaling disrupted.  
 
 
 Human primary hepatocytes treated with uremic sera develop insulin resistance 
leading to increased gluconeogenesis. 
 
 
 In vitro culture of human primary hepatocytes with uremic sera leads to increased 
lipogenesis and the accumulation of significantly more intra- and extracellular 
lipids as compared to culturing the same cells with healthy sera. 
 
 
 The central elements regulating the synthesis and release of bile acids appear to be 
unchanged in cells exposed to uremic sera.   
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